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This work is focused on understanding protein function by describing how 
paralogous proteins with overlapping and distinct functions interact with their substrates 
and with other proteins. Two model systems are the subject of this research: (1) the 
stereospecific dehydrogenases R- and S-HPCDH, and (2) the zinc knuckle proteins Air1 
and Air2. 
 R- and S-HPCDH are homologous enzymes that are central to the metabolism of 
propylene and epoxide in the soil bacterium Xanthobacter autotrophicus. The bacterium 
produces R- and S-HPCDH simultaneously to facilitate transformation of R- and S-
enantiomers of epoxypropane to a common achiral product 2-ketopropyl-CoM (2-KPC). 
Both R- and S-HPCDH are highly stereospecific for their respective substrates as each 
enzyme displays less than 0.5% activity with the opposite substrate isomer. Presented 
here are substrate-bound x-ray crystal structures of S-HPCDH. Comparisons to the 
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previously reported product-bound structure of R-HPCDH reveal structural differences 
that provide each enzyme with a distinct substrate binding pocket. These structures 
demonstrate how chiral discrimination by R- and S-HPCDH results from alternative 
binding of the distal end of substrates within each substrate binding pocket,  providing a 
structural basis for stereospecificity displayed by R- and S-HPCDH.  
 Air1 and Air2 are homologous eukaryotic proteins that individually function 
within a trimeric protein complex called TRAMP.  In the nucleus, TRAMP participates in 
RNA surveillance, processing, and turnover by stimulating the 3’-5’ exonucleolytic 
degradation of targeted RNAs by the nuclear exosome. Previous studies have indicated 
that within TRAMP Air1 and Air2 provide crucial protein-protein interactions that link 
the individual subunits of the complex. However, the mechanistic details of these protein-
protein interactions are poorly understood.  The work in this dissertation has 
characterized a previously unknown binding interface between Air2 and another TRAMP 
component, the helicase Mtr4. This interaction may explain how helicase activity is 
modulated in TRAMP. In addition to TRAMP protein interactions, preliminary studies 
have identified a small region of Air1 that is required for modulating the activity of a 
protein that is not found in TRAMP, the methyltransferase Hmt1. Collectively, these 
studies provide important characterization of Air1 and Air2 protein-binding interactions, 
and establish a foundation for future research efforts aimed at exploring Air protein 
function. 
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A thorough understanding of protein function requires knowledge of how proteins 
interact with their substrates and with other proteins. The work entailed in this 
dissertation describes the binding interactions of proteins from two different model 
systems: (1) the dehydrogenase enzymes R- and S-HPCDH and (2) the zinc knuckle 
proteins Air1 and Air2. 
R- and S-HPCDH are highly similar enzymes (42% identical) that function in a 
unique metabolic pathway found in the soil bacterium Xanthobacter autotrophicus. The 
bacterium produces R- and S-HPCDH simultaneously to facilitate the transformation of 
two different forms of the organic molecule epoxypropane to a common product that can 
be further metabolized and used as a source of energy for the microbe. R- and S-HPCDH 
are highly specific for either the right-handed or left-handed form (R- or S- forms) of 
their substrate molecules, respectively. Presented here are x-ray crystal structures 
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(structural models) of S-HPCDH. Comparisons to the previously reported structure of R-
HPCDH reveal structural differences that provide each enzyme with a distinct preference 
for binding and processing either the R- or S- form of their substrate molecules, 
demonstrating a structural basis for substrate preference by R- and S-HPCDH. 
Air1 and Air2 are highly similar (45% identical) eukaryotic proteins that 
individually function within an essential three-protein complex called TRAMP. In the 
nucleus, TRAMP functions in RNA surveillance which is used to monitor different types 
of RNA molecules found in the nucleus and stimulate the degradation of any RNAs that 
need to be further processed or eliminated. Previous studies have indicated that Air1 and 
Air2 are involved in mediating crucial protein-protein interactions that link together the 
individual protein subunits of TRAMP.  The work in this dissertation characterizes a 
previously unknown binding interface between Air2 and another TRAMP protein-
component, the helicase Mtr4. Importantly, this interaction may explain how the 
functional activity of Mtr4 is modulated upon formation of TRAMP, a critical TRAMP 
functionality. In addition to protein interactions within TRAMP, this work has also 
identified a small region of Air1 that binds and regulates the activity of a protein that is 
not part of TRAMP, the methyltransferase Hmt1.  Collectively, these studies reveal 
important and previously unknown binding interactions of the multifaceted proteins Air1 



















               Page 
ABSTRACT.......................................................................................................................iii 
PUBLIC ABSTRACT.........................................................................................................v 
LIST OF TABLES..............................................................................................................ix 
LIST OF FIGURES.............................................................................................................x 
CHAPTER 
1. INTRODUCTION I: DEHYDROGENASES OF BACTERIAL EPOXIDE     
CARBOXYLATION...................................................................................1 
 
2.  CRYSTAL STRUCTURES OF S-HPCDH REVEAL DETERMINANTS            
OF STEREOSPECIFICITY FOR R- AND S-HYDROXYPROPYL- 
COENZYME M DEHYDROGENASES..................................................27 
3.   INTRODUCTION II: AIR PROTEINS AND RNA         
REGULATION.........................................................................................48 
 
4. A COMPREHENSIVE DISCRIPTION OF METHODS USED TO 
CHARACTERIZE AIR PROTEINS.........................................................74 
 
5. TRAMP ASSEMBLY INVOLVES BINDING INTERACTIONS OF 
THE N-TERMINUS OF AIR2 AND THE RECA DOMAINS OF 
MTR4........................................................................................................98 
 









LIST OF TABLES 
Table               Page 
2-1 Data collection and refinement statistics for S-HPCDH structures.......................33 
4-1 Buffer solutions for Air protein preparations.........................................................79 

























LIST OF FIGURES 
Figure               Page 
1-1 Oxidation of propylene by catalyzed by alkene monooxygenase ........................... 4 
1-2      Biological strategies of epoxide metabolism ........................................................... 6 
1-3      Three steps of the epoxide carboxylation pathway in X. autotrophicus Py2 .......... 9 
1-4 Covalent addition of CoM to epoxypropane by epoxyalkane coenzyme M 
transferase………………………………………………………………………..10 
 
1-5      Oxidation of R-HPC by R-hydroxypropyl-coenzyme M dehydrogenase………..12 
1-6 Enzymatic steps catalyzed by the DSOR family of enzymes……………………14 
1-7 Ribbon diagram of a classical SDR enzyme……………………………………..17 
1-8 Ribbon diagram of R-HPCDH…………………………………………………...20  
2-1 R-HPCDH and S-HPCDH convert R-and S-hydroxypropyl CoM to a common 
product 2-ketopropyl-CoM………………………………………………………28 
 
2-2 Tetrameric structure of S-HPCDH……………………………………………….35 
2-3 Monomeric structure of S-HPCDH……………………………………………...36 
 
2-4 Structural differences between R-HPCDH and S-HPCDH……………………...40 
 
2-5 Distinct substrate binding pockets are observed in R-HPCDH- and S-HPCDH...42 
2-6 S-HPC and a model of R-HPC within the active site of the S-HPCDH ternary 
complex..................................................................................................................44 
 
3-1 Tramp mediated RNA degradation by TRAMP4…..............................................53 
3-2 Air1 and Air2 sequence alignment........................................................................56 
 




3-4 Crystal structure of Mtr4………………...………………….................................64 
 
4-1 Air1 and Air2 codon optimized expression constructs..........................................83 
 
4-2 Air1 (N-ZnK5) binds tRNAiMet in vitro.................................................................96 
 
5-1 A 29 amino acid peptide in the N-terminus of Air2 interacts with the RecA 
domains of Mtr4……………………………………………………………..….104 
 
5-2 Air1 residues 1-41 bind to Mtr4 in vitro ………………….……………………106  
 
5-3 Binding interactions between the N-terminus of Air2 and Mtr4Fist are not  
 observed in vitro………………………………………….………….…………109 
 
6-1 Characterized protein-protein and RNA binding interfaces of Air proteins........117 
 
6-2 N. terminus sequence alignment of Air protein homologues in yeast………….120 
 
6-3 Protein binding analysis of Air proteins and Hmt1.............................................124 
 
6-4  Air2 (N-ZnK5)-Hmt1 crystals and X-ray diffraction…………………………. 126 
 
6-5 Sequence alignment of Air1 and Air2 zinc knuckles 4-5………………………128 
CHAPTER 1 
INTRODUCTION I: DEHYDROGENASES OF BACTERIAL EPOXIDE 
CARBOXYLATION 
 
During the last century, the increase of human dependence on industrial chemical 
processes has resulted in the release of a myriad of potentially detrimental carbon based 
compounds into the environment. These environmental contaminants include commonly 
recognized greenhouse gases like CO and CO2, and also include many short-chain 
unsaturated hydrocarbons such as ethylene, propylene, butylene, and styrene; all of which 
are produced on a massive scale worldwide. The epoxides formed from alkenes and their 
halogenated counterparts are especially reactive molecules that may have toxic, 
mutagenic, and carcinogenic effects on biological organisms [1, 2]. High concentrations 
of these hazardous molecules can often be detected in soils and ground water samples in 
areas near industrial sites [3], posing a great risk to the local biota and to human health. 
Interestingly, several bacterial species have been identified that are capable of 
detoxifying and converting short chain (C2-C6) alkenes and epoxides into usable non-
reactive central metabolites. One such species is Xanthobacter autotrophicus Py2, which 
is capable of growth using propylene or its corresponding epoxide, epoxypropane, as its 
sole source of carbon and energy [4]. Bacteria containing such metabolic pathways for 
converting alkenes and epoxides into non-harmful molecules are generally believed to 
play an essential role in the re-mineralization of this carbon in the global carbon cycle 
[3].  
It is of considerable interest to understand the biological mechanisms used by 
microbes to eliminate various toxic hydrocarbons, as both the whole organisms and the 
2 
enzymes comprising their novel metabolic pathways have potential bioremediation and 
biotechnological applications. The focus of research presented in this dissertation is to 
gain further insight into the metabolic pathway of epoxide degradation used by the 
bacterium X. autotrophicus Py2. Of particular interest are two stereospecific 
dehydrogenases which allow the bacterium to metabolize both R- and S- enantiomers of 
epoxypropane.   
 
Sources of propylene and epoxypropane 
 Propylene and its oxidized derivative epoxypropane are generated from both 
anthropogenic and biogenic sources. Propylene is a three carbon alkene that is produced 
primarily as a byproduct of petroleum refining wherein the process of steam cracking 
large hydrocarbon feed-stocks is used to produce other smaller hydrocarbons such as 
ethylene. In 2011 it was estimated that the global capacity of industrial propylene 
production was nearly 70 million metric tons and expected to increase at a rate of 5% 
annually [5]. In the United States, nearly two thirds of the propylene that is produced is 
used for the manufacturing of plastics in the form of polypropylene, and 17% is used 
directly for the production of epoxypropane (also known as propylene oxide) [6]. 
Epoxypropane is a highly reactive molecule that is used as a versatile chemical 
intermediate for the production of many other compounds. The reactivity of 
epoxypropane stems from its strained three-membered ring and propensity to undergo 
nucleophilic attack by a number of different compounds including organic and inorganic 
acids and bases, alcohols, and amines. The major industrial products derived from 
epoxypropane include polyglycol ethers used in polyurethane foams, and propylene 
3 
glycols which are used in a number of applications including polyester resins, chemical 
solvents, pharmaceuticals, foods, antifreeze, and many others. By volume propylene and 
epoxypropane are amongst the top 50 chemicals produced worldwide [7]. As the 
production of these potentially toxic compounds continues to increase, the volume of 
propylene and epoxypropane that are emitted into local environments also increases. For 
example, since 1983 the annual US emissions of propylene and epoxypropane have been 
estimated to have increased from around 440 thousand tons to over 700 thousand tons [8, 
9]. 
In addition to industrial production, propylene and epoxypropane are also 
produced, albeit at a much smaller scale, from biological sources. Propylene for example 
is one of many small alkenes that are generated and excreted by plant vegetation and 
fungi. Propylene is also formed as a product of the combustion of organic materials, i.e. 
burning of biomass and fossil fuels [9]. Epoxypropane and other aliphatic epoxides can 
be produced biologically in some eukaryotic pathways and by several alkene oxidizing 
bacetria. The epoxides generated in vivo are generally short lived intermediate molecules 
that are produced by the initial step in biological pathways that are used for alkene 
detoxification, or in metabolic pathways that allow some bacteria to utilize alkenes and 
epoxides as carbon and energy sources. In each type of pathway, epoxides are produced 
by the oxidation of alkenes by alkene monooxygenase enzymes. Alkene monooxygenases 
(AMOs) typically exhibit broad substrate specificities and convert various alkenes into 
epoxides by incorporating O2 across the olefin bond of the alkene, as illustrated for the 
substrate propylene and product epoxypropane in Figure 1-1. Notably, most AMOs are 
somewhat stereoselective producing both R- and S- enantiomers of aliphatic epoxides. 
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         Figure 1-1. Oxidation of propylene catalyzed by alkene monooxygenase.  
 
 
The monooxygenases used in alkene detoxification pathways include the heme 
containing family of cytochrome P450 enzymes found throughout eukaryotes and 
prokaryotes [10], and other non-heme containing monooxygenases found exclusively in 
prokaryotes [11-13].  AMOs used to generate aliphatic epoxides such as epoxypropane 
for carbon and energy sources have been isolated from two bacterial species, X. 
autotrophicus Py2  and R. rhodochrous B-276 [14, 15]. In these bacteria, alkene 
metabolism is initiated by the epoxidation of alkenes (i.e. propylene to epoxypropane) by 
a non-heme di-iron type AMO.   
 
Biological Reactivity of Epoxides  
Epoxides are likely to have adverse effects on biological systems. The strong 
electrophilic nature of epoxides allows them to readily form covalent adducts with a 
number of biological macromolecules, including DNA, RNA, and proteins [2]. In DNA 
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and RNA, the reactive nucleophiles are nitrogen atoms of purine and pyrimidine bases. In 
proteins, the reactive nucleophiles include nitrogen atoms of the imidazole ring of 
histidine, and sulfur atoms found in the side chains of cysteine and methionine residues. 
In each case, the biological nucleophile attacks and opens the epoxide oxirane ring, 









Such modifications of protein and nucleic acids have profound effects on cellular 
functions. Therefore, many aliphatic epoxides, including epoxypropane, are characterized 
as having toxic, mutagenic, and carcinogenic effects on living organisms [1, 2]. For 
organisms that contain alkene degradation pathways, the initial conversion of an alkene 
to epoxide results in a more reactive and potentially  harmful compound that must be 
quickly transformed into a non-harmful molecule.  
 
Biogenic remediation of epoxides  
To circumvent the toxic effects of epoxide reactivity, microbial systems use 
nucleophiles other than nucleic acids and protein to react with epoxides and render them 
inactive as electrophiles. In these reactions, epoxides are either converted into a less 
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detrimental compound which can then be excreted by the microbe (detoxification 
pathway), or converted into an organic metabolite that can be used as a source of carbon 
and energy via productive metabolism (metabolic pathway). The differences between the 
pathways lay in the different nucleophiles that are used to react with the epoxide and the 
fate of the product that is formed.  In the case of detoxification pathways, many types of 
bacteria contain detoxification enzymes such as glutathione S-transferases (GSTs) and 
epoxide hydrolayses which use glutathione or water, respectively, as nucleophiles to 
attack and open the epoxide ring [16-18] (Figure 1-2A, B). The less reactive product can 
then be excreted by the bacterium or used for other biological purposes. In the case of 
productive metabolism, several pathways have been characterized in which the first step 
involves the nucleophilic addition of a biological molecule such as glutathione or water, 
as described above for detoxification pathways. Another strategy for metabolizing 
epoxides is found in styrene utilizing bacteria where metabolism of styrene proceeds by 
isomerization of styrene oxide to the corresponding aldehyde phenylacetaldehyde [19] 
(Figure 1-2C). Another less common strategy is used by several aerobic bacteria that 
have been isolated with propylene and epoxypropane as the only source of carbon and 
energy. In these pathways a thiol of the atypical cofactor, 2-mercaptoethanesulfonate 
(coenzyme M; CoM), is used as the reactive nucleophile which attacks and opens the 
epoxide ring, generating a coenzyme M conjugate (Figure 1-2D). The coenzyme M 
conjugate is then further metabolized in a series of reactions including a final 
carboxylation step producing a molecule of acetoacetate which can then be transformed 
into acetyl-CoA for energy production. This unique pathway, which has become known 





the soil bacterium X. autotrophicus [20, 21] strain Py2, and later extended to R. 
rhodochrous strain B276 [22]. Since then, homologues of each of the four enzymes of the 
pathway have been found in other alkene metabolizing bacteria including additional 
strains of Xanthobacter and R.rhodochrous, Mycobacterium, Pseudomonas, and 
Alcaligenes. Overall, the pathway is a very effective way to convert a hazardous 3-carbon 
compound into a relatively inert 4-carbon metabolite. Throughout the last decade, there 
has been significant interest in understanding the various enzymatic steps of bacterial 
epoxide carboxylation, as each of the enzymes in the pathway and the various bacterial 
Figure 1-2. Biological strategies of epoxide metabolism. (A) Glutathione 
transferase, (B) epoxide hydrolase, (C) Styrene oxide isomerase, (D) 
epoxyalkane:CoM transferase. 
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species that contain them have potential bioremediation and biotechnological 
applications.   
 
The epoxide carboxylation pathway of X. autotrophicus Py2 
 As mentioned previously, the first step in metabolizing short-chain alkenes like 
propylene is the oxidative conversion of the alkene into its corresponding epoxide by 
AMOs. In X. autotrophicus Py2 the AMO used is a multicomponent NADH-dependent 
enzyme that is highly stereoselective, as demonstrated by propylene oxidation in which 
the AMO produces a racemic mixture of 95% R-epoxypropane and 5% S-epoxypropane 
[15, 21]. In the presence of CO2, both enantiomers of epoxypropane can be effectively 
metabolized by the bacterium, as each is transformed into a molecule of acetoacetate 
using a three-step four-enzyme pathway called the epoxide carboxylation pathway [21]. 
The pathway converts R-and S- enantiomers of a variety of short-chain aliphatic epoxides 
into a β-keto acid which can then be converted into two molecules of acetyl-CoA (Figure 
1-3). Although aliphatic epoxides of varying chain lengths (C2-C6) can be effectively 
metabolized via the epoxide carboxylation pathway [3], the most extensively 
characterized substrate is epoxypropane [23-25]. Therefore, the following descriptions of 
the pathway are in the context of the conversion of epoxypropane to the β-keto acid 
acetoacetate. Experimental evidence has indicated that the reactions catalyzed at each of 
the three steps are fully reversible. The pathway requires NADPH, NAD+, and fixes a 
molecule of CO2. 
A multitude of biochemical and structural studies have revealed unique functions 
and many mechanistic details of the enzymes at each of the three steps of the epoxide 























Figure 1-3. Three steps of the epoxide carboxylation pathway in X. autotrophicus Py2. 
Enzymes catalyzing reactions are written in italics. Green box indicates the second step 
which is catalyzed by the two enzymes R-hydroxypropyl-CoM dehydrogenase (R-




nucleophilic addition of the cofactor CoM. This reaction is catalyzed by the enzyme 
epoxyalkane coenzyme M transferase (EaCoMT) [20, 23, 26]. Sequence analysis 
indicates that EaCoMT belongs to the Zn-containing alkyl transferase family of enzymes 
which catalyze nucleophilic substitution reactions using activated thiols as nucleophiles. 
Like other Zn-containing alkyl transferases, EaCoM activates its reactant thiol group 
(thiol of CoM) by coordinating it to a Zinc ion. The metal ion coordination lowers the 
pKa of the CoM thiol by 1.7 pH units (9.1 to 7.4), facilitating nucleophilic attack by the 
now deprotonated thiolate, and subsequent covalent addition of CoM to the aliphatic 
epoxide (Figure 1-4) [27, 28].  EaCoMT is unique in the family of Zn-containing alkyl  
transferases because it catalyzes a nucleophilic addition reaction rather than a 
nucleophilic substitution reaction. The utility of CoM in the pathway is evident in the 
remaining two steps, as each of the following three enzymes in the pathway use the 











Figure 1-4. Covalent addition of CoM to epoxypropane by 
epoxyalkane coenzyme M transferase (EaCoMT). A Zinc ion 
activates the CoM thiol (colored red) for nucleophilic attack 
and subsequent addition of CoM to epoxypropane, producing 
R- and S-hydroxypropyl CoM (R- and S- HPC). 
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properly orient substrates for catalysis [29-33]. 
The second step in the pathway, and the focus of Chapter 2 of this dissertation, 
involves two dehydrogenase enzymes, (R)-hydroxypropyl-coenzyme M dehydrogenase 
(R-HPCDH) and (S)-hydroxypropyl-coenzyme M dehydrogenase (S-HPCDH). These are 
homologous enzymes (42% sequence identity) that are highly stereospecific for either the 
R- or S-enantiomers of HPC. In this step, both R- and S- HPCDH are used in concert to 
convert each enantiomer of HPC into the same achiral product 2-ketopropyl CoM (2-
KPC). A remarkable feature of R- and S-HPCDH is their ability to discriminate between 
R- and S- enantiomers of HPC, as each enzyme exhibits only 0.5%-1% activity when 
using the opposite HPC isomer as a substrate [21]. R- and S-HPCDH are members of the 
classical short-chain dehydrogenase reductase (SDR) superfamily of enzymes. Enzymes 
in this family are NAD(P)(H) dependent enzymes that share a common catalytic tetrad 
(Tyr–Lys–Ser–Asn) and catalytic mechanism, as shown for the conversion of R-HPC to 
2-KPC in Figure 1-5. In the mechanism shown, the role of the catalytic tetrad residues 
and the chemistry around the chiral carbon (C2 in R-HPC) is analogous to the general 
mechanism described for other SDR enzymes [34, 35]. Specifically, the tetrad serine 
assists in positioning the hydroxyl group of the substrate near the catalytic tyrosine. The 
tetrad lysine has a dual role in coordinating NAD+ and in lowering the pKa of the catalytic 
tyrosine hydroxyl group through a proton relay that connects the tyrosine, through 
hydrogen bonding, to the bulk solvent. The proton relay path is generated through side 
chains of three of the catalytic tetrad residues (Tyr-Lys-Asn), hydroxyl group of the 
nicotinamide ribose, and water molecules that lead away from the active site to bulk 
solvent.  In its deprotonated form, the tyrosine acts as a general base abstracting a proton 
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from the C2 hydroxyl group of the substrate. A hydride is simultaneously transferred 
from the C2 carbon to NAD+, forming NADH and the ketone 2-ketopropyl coenzyme M 





The final step in the epoxide carboxylation pathway is the CO2 dependent 
carboxylation of 2-KPC and the regeneration of CoM by the enzyme NADPH:2-
ketopropyl-CoM carboxylase/oxidoreductase (2-KPCC).  Sequence analysis has indicated 
that 2-KPCC belongs to the FAD containing NADPH:disulfide oxidoreductase (DSOR) 
family of enzymes [36]. All enzymes in this family employ a general mechanistic 
strategy in which a reduced form of flavin adenine dinucleotide (FADH) is used to reduce 
a conserved cysteine disulfide bond in the active site, which activates the cysteine 
residues for catalysis [37].  The cysteine residues proximal and distal, with respect to 
Figure 1-5. Oxidation of R-HPC by R-hydroxypropyl-coenzyme M 
dehydrogenase (R-HPCDH). Binding of the sulfonate moiety of CoM is 
indicated by a grey circle. Catalytic tetrad residues (Ser-Tyr-Lys-Asn) are 
shown. Tyr155 acts as a general base and a hydride is transferred from R-HPC to 
NAD+. A proton relay connects catalytic residues to bulk solvent through water 
mediated hydrogen bonding. Image was modified from Sliwa, et al. 2010. 
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FAD, are termed the flavin and interchange thiols, respectively. Typical DSOR enzymes 
use the activated thiols to catalyze the two electron reduction of a substrate disulfide bond 
(Figure 1-6), the interchange thiol attacks one of the sulfur atoms of a substrate disulfide 
bond, resulting in disulfide bond cleavage and a mixed disulfide formed between the 
interchange thiol and the substrate disulfide. The catalytic cysteine pair is then re-




Figure 1-6. Enzymatic steps catalyzed by the DSOR family of enzymes. A substrate with 
an oxidized disulfide bond is attacked by the interchange thiol. Oxidation of the catalytic 
cysteine pair reduces the covalently bound substrate and the reduced substrate is released. 
 
2-KPCC is unique amongst DSOR enzymes in at least two respects. First, it 
catalyzes the reduction of a thioether rather than a disulfide bond. Second, it is the only 
known carboxylase within the DSOR family. Mechanistic studies [38] have provided 
evidence for a mechanism where the interchange thiol attacks the thioether bond of 2-
KPC resulting in a mixed disulfide between CoM and the interchange thiol, and the 
formation of an enolacetone anion. The enolacetone anion then undergoes carboxylation 
producing acetoacetate.  Re-oxidation of the catalytic cysteine pair releases CoM, which 
can then be reused in the in the first step of the epoxide carboxylation pathway.  
The initial mechanistic studies of 2-KPCC left many unanswered questions about 
the unique features of its mechanism, including how the substrate is bound, and how the 
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highly reactive enolacetone anion is stabilized and carboxylated. A variety of X-ray 
crystal structures have provided significant insights to these questions [32, 39, 40]. The 
different crystal structures of 2-KPCC include; a substrate-free form (apo-enzyme), 
enzyme bound to the substrate 2-KPC, enzyme with a mixed disulfide of CoM, and a 
CO2 bound form. The 2-KPC bound structure revealed that the enzyme uses two 
positively charged amino acids to bind the sulfonate moiety of CoM. Upon substrate 
binding a conformational change occurs that creates a hydrophobic pocket around the 
substrate 2-KPC which appears to be accessible only by a small hydrophobic channel, 
presumably for CO2. A hydrogen bonding network was also identified in the 2-KPC 
bound structure which has been proposed to stabilize the enolacetone anion. The 
hydrogen bonding network consists of an ordered water molecule that is hydrogen 
bonded to the carbonyl oxygen of 2-KPC and two histidine residues (H84 and H137). It is 
presumed that hydrogen bonding by the His-oriented water molecule serves to both 
stabilize the enolacetone anion and orient its methylene group for attack on CO2.        
The novelty of the epoxide carboxylation pathway is exhibited at each of the three 
steps. (1) The usage of CoM, (2) the use of two stereospecific dehydrogenases, and (3) 
the fixation of CO2. The discovery of CoM as the 4-carbon carrier in this pathway and the 
fixation of CO2 were surprising and unprecedented. Prior to its discovery in this bacterial 
pathway, CoM the smallest known biological cofactor, had only been identified to 
function in methanogenisis in archaebacterial [41-43]. A Carboxylation step consuming 
CO2 had also never been demonstrated in any metabolic pathway used for small 
hydrocarbon metabolism. The simultaneous usage of two homologous dehydrogenases in 
the same pathway is also a very rare occurrence throughout biology. 
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 As mentioned above, extensive biochemical and structural studies have revealed 
novel functions and mechanisms of the enzymes at each of the pathway steps. However, 
the mechanisms that govern stereospecificity of the dehydrogenases R- and S-HPCDH is 
a feature that unlike other novel aspects of the pathway, has not been fully characterized.  
In addition, because R- and S-HPCDH are homologous enzymes catalyzing the same 
reaction but with opposite stereochemistry, they are a great model for studying 
mechanisms of stereospecificity in enzyme catalysis, and more specifically, the 
mechanisms controlling specificity within the SDR superfamily of enzymes.  
 
SDR superfamily of enzymes 
 R-and S-HPCDH belong to the classical short-chain dehydrogenase/reductase 
(SDR) super family of enzymes. The SDR family represents one of the largest and oldest 
enzyme families known with over 60,000 members annotated in sequence databases [44]. 
The characteristics that define this protein family are chain lengths of approximately 250 
amino acids, a large N-terminal domain (Rossman fold) containing a common sequence 
motif (TGxxxGxG) for binding NAD(P)(H), a conserved catalytic tetrad (serine, tyrosine, 
lysine, asparagine), and a small C-terminal domain that typically functions in substrate 
binding . SDR enzymes are arguably the most widely distributed group of enzymes. 
Members have been identified throughout the three domains of life and represent multiple 
enzyme classes including isomerases, transferases, lyases, and oxidoreductases. Although 
these enzymes have conserved residues for binding NAD(P)(H) and catalysis, they have 
very broad substrate specificities including substrates such as xenobiotics, steroids, 
sugars, and aliphatic alcohols [34, 44, 45].   
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  Another interesting feature of the SDR superfamily is that despite relatively low 
sequence homology (15-30% sequence identity), and diverse substrate preferences, the 3-
dimensional structures of SDR enzymes (over 400 in the PDB) are clearly homologous 
with nearly super-imposable tertiary and quaternary structures. The predominant 
structural feature of SDR proteins is a large N-terminal domain composed of a common 
α/β-folding pattern characterized by a central β-sheet typical of a Rossmann-fold with 
three α-helices on each side (Figure 1-7). It is generally understood that members of the 
SDR superfamily utilize this common N-terminal Rossman fold domain as a structural 
scaffold in which minor modifications to a smaller C-terminal extension (the C-terminal 
domain) confer large differences in substrate preference.  
The Rossman fold dinucleotide binding motif is the most common fold found in the 
Protein Data Bank (PDB), and the various enzymes of the SDR superfamily highlight the 
versatility of this fold in being able to accommodate diverse substrates for various types 
of chemical transformations. Because of this versatility, many SDR enzymes have been 
targets of enzyme engineering for biocatalysis [46-50]. Of particular interest in multiple 
industries is the engineering of stereospecific and stereoselective dehydrogenases that can 
be used to produce certain alcohol isomers or clarify racemic mixtures. The potential 
commercial value of dehydrogenases within the SDR superfamily for stereospecific and 
stereoselective transformations has stimulated significant interest in elucidating the  
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Figure 1-7. Ribbon diagram of classical SDR enzyme (3α/20β HSD; PDB: 2HSD)          
(A) Tetramer. (B) Monomer; the Rossman fold is depicted with β-strands in red and α-
helicies in light blue. The C-terminal domain is colored yellow and NAD+ is shown as 
sticks.  
 
catalytic and structural features that govern there mechanisms [49, 51, 52]. Furthermore, 
once biochemical and molecular details of a particular enzyme is known, enzymatic 
properties such as specificity and selectivity can be modulated through directed evolution 
or mutagenesis to fine-tune the enzyme for various functions. 
Within the SDR superfamily there are numerous stereospecific enzymes. However, 
few stereospecific enzymes have been found to function simultaneously with a 
homologous partner-enzyme. Accordingly, R- and S-HPCDH represent a unique and 
ideal model system to examine stereospecificity within the SDR superfamily because 
they are homologous proteins performing essentially identical chemistry in the same 
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pathway, yet both enzymes are highly specific for their respective substrates (R-HPC or 
S-HPC). 
 
Mechanistic studies of R-and S-HPCDH 
Both R and S-HPCDH have been recombinantly expressed, purified, and 
characterized biochemically. Mutagenesis studies have revealed that like the enzyme 2-
KPCC (the following step in the pathway),  Both R- and S-HPCDH possess two 
positively charged amino acids that are involved in binding the negatively charged 
sulfonate tail (sulfonate moiety of CoM) of the substrate. These residues have been 
identified as R152 and R196 in R-HPCDH, and R211 and K214 in S-HPCDH [53, 54]. 
Site directed mutagenesis of these residues in either enzyme dramatically alters their 
ability to oxidize natural substrates, whereas the same mutations do not alter the 
oxidation of similar substrates lacking the sulfonate moiety [33, 54]. These studies 
suggest that in each enzyme the sulfonate binding amino acids are important contributors 
for aligning the natural substrates properly for catalysis. From these studies, it was also 
hypothesized that alternative positioning of the substrate binding residues within each 
enzyme could be a contributing factor to their opposite stereospecificity.         
 Inhibition and kinetic analyses have suggested differences in how each enzyme 
controls stereospecificity. Inhibition studies showed that the substrate S-HPC is a 
competitive inhibitor of R-HPC oxidation in R-HPCDH, with a Kic nearly identical to the 
Km of the natural substrate [54]. This observation indicated that R-HPCDH has a similar 
preference for binding either substrate (R-HPC or S-HPC). Similar studies performed 
with the S-HPCDH enzyme showed that the R-HPC substrate is not a competitive 
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inhibitor of S-HPC oxidation [33], indicating that unlike R-HPCDH, the S-enzyme has a 
much greater preference for binding its natural substrate S-HPC over R-HPC. 
 To help clarify differences observed by inhibition studies, a side-by-side kinetic 
analysis of R- and S-HPCDH for oxidizing each substrate isomer (R-HPC and S-HPC) 
was performed [33]. The catalytic efficiencies (kcat/Km) of each enzyme for its “natural” 
substrate isomer are in the range of 1 to 8 x 105. Whereas the catalytic efficiencies of 
each enzyme using the opposite substrate isomers are each nearly three-orders of 
magnitude lower. Thus, as previously described, both enzymes are highly effective at 
discriminating between different HPC stereoisomers. Interestingly, this kinetic study 
revealed that stereospecificity in the two enzymes is governed by different kinetic 
mechanisms. In the R-enzyme, the difference in catalytic efficiencies between the two 
substrates is governed largely by a difference in the values of kcat (turnover rate), which is 
402 times lower when using S-HPC as substrate compared to the R-HPC substrate. 
Alternatively, in the S-enzyme the difference in catalytic efficiencies between the two 
substrates is predominated by a large difference in the value of Km for each substrate (Km 
is 209 times higher for R-HPC compared to S-HPC). This increase in Km may be 
indicative of an inherent inability of the R-HPC substrate to effectively bind within the 
catalytic site of the S-enzyme.  
In addition to biochemical characterization, R-HPCDH has been characterized 
structurally [30]. A 1.8 Å crystal structure of R-HPCDH bound to NAD+ and the product 
2-KPC showed that the enzyme is structurally homologous to other members of the SDR 
superfamily. Specifically, like many other SDR enzymes its crystal structure is a tetramer 















terminal domain is in the form of a Rossman fold composed of seven parallel β-strands 
flanked on each side by three α helices. Unambiguous electron density of residues bound 
to 2-KPC confirmed that R152 and R196 are used to bind directly to the sulfonate moiety 
of CoM.  Unfortunately, the positioning of the reactive carbonyl group of 2-KPC at the 
catalytic site could not be observed in the crystal structure. Instead, the structure exhibits 
the 2-KPC carbonyl group more than seven angstroms from the catalytic tyrosine, 
presumably representing a conformation of 2-KPC exiting the active site [30]. In an 
attempt to identify structural differences between R- and S-HPCDH, The R-HPCDH 
structure was used to construct a homology model of S-HPCDH [33]. As expected, the 
Figure 1-8. Ribbon diagram of R-HPCDH (PDB: 2CFC). (A) Tetramer. (B) Monomer; 
Rossman fold is depicted with β-strands in red and α-helicies in light blue. The C-
terminal domain is colored yellow and NAD+ is shown as lines. The product 2-KPC is 
shown with the sulfonate moiety of CoM bound by R196 and R152. 
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homology model predicted nearly opposite positioning of S-HPCDH sulfonate binding 
residues compared to the sulfonate binding residues in R-HPCDH. 
Taken together, results from biochemical and structural studies have been used to 
formulate a model for stereospecificity in R- and S-HPCDH. According to this “mirror 
image” model, opposite stereospecificity of R- and S-HPCDH is obtained via opposite 
positioning of sulfonate binding residues in each enzyme, which results in reverse 
orientations of the chemical groups attached to the  C2 carbon (chiral carbon) of each 
substrate  relative to a common catalytic site [30, 33, 54]. The different kinetic values 
described above for each enzyme can be rationalized by this model in the following way:  
In the R-enzyme both substrates can bind at the catalytic site with similar affinity, but a 
960-fold increase in catalytic efficiency using R-HPC over S-HPC is achieved because 
the R-HPC reactive group is in the proper stereo-orientation for catalysis. When the S-
HPC substrate binds to the R-enzyme its C2 hydrogen is oriented in the opposite direction 
pointing away from NAD+. This opposite orientation inhibits direct hydride transfer from 
C2 of the substrate to NAD+, and results in a 402-fold decrease in the value of kcat for 
oxidation of S-HPC compared to R-HPC.  In the S-enzyme, the R-HPC substrate cannot 
effectively bind at the catalytic site because its C2 methyl group is not accommodated 
due to steric clashes with amino acid side chains or NAD+, resulting in a 209-fold 
increase in the Km value for oxidizing the R-HPC substrate compared to the S-HPC 
substrate.  Although this model is plausible, it does not describe the actual structural 
differences that may account for the observed kinetic differences between the enzymes, 
and it cannot be convincingly validated without a comparative structural analysis 
between the two enzymes and their substrate binding interactions at the catalytic site.  
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Concluding Remarks 
 The mechanism that governs stereospecificity of R- and S-HPCDH is one of the 
last outstanding questions regarding the remarkable pathway of bacterial epoxide 
carboxylation. The work described in Chapter 2 of this dissertation provides the first side-
by-side structural comparison between R- and S-HPCDH, and the first structural analysis 
of how an HPC substrate is aligned within the active site of one of these enzymes (S-
HPCDH). The results from these studies reveal unique substrate binding pockets 
displayed by each enzyme, a structural role of methionine residues within each active 
site, and a structural basis for stereospecificity displayed by R- and S-HPCDH. 
Furthermore, the structural mechanisms used by this pair of dehydrogenases to 
discriminate between two highly similar substrates may provide valuable insight for the 
rational design of other enzymes within the SDR superfamily. 
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CRYSTAL STRUCTURES OF S-HPCDH REVEAL DETERMINANTS OF 





 (R)- and (S)-hydroxypropyl-coenzyme M dehydrogenases (R- and S-HPCDH) are 
stereospecific enzymes that are central to the metabolism of propylene and epoxide in 
Xanthobacter autotrophicus. The bacterium produces R- and S-HPCDH simultaneously 
to facilitate transformation of R- and S-enantiomers of epoxypropane to a common 
achiral product 2-ketopropyl-CoM (2-KPC). Both R- and S-HPCDH are highly specific 
for their respective substrates as each enzyme displays less than 0.5% activity with the 
opposite substrate isomer. In order to elucidate the structural basis for stereospecificity 
displayed by R- and S-HPCDH we have determined substrate bound crystal structures of 
S-HPCDH to 1.6 Å resolution. Comparisons to the previously reported product-bound 
structure of R-HPCDH reveal that although the placement of catalytic residues within the 
active site of each enzyme is nearly identical, structural differences in the surrounding 
area provide each enzyme with a distinct substrate binding pocket. These structures 
demonstrate how chiral discrimination by R- and S-HPCDH results from alternative 
binding of the distal end of substrates within each substrate binding pocket. 
  
1Coauthored by Jeremy W. Bakelar, Dariusz A. Sliwa, and Sean J. Johnson 




Propylene metabolism in the soil bacterium Xanthobacter autotrophicus strain 
Py2 involves the conversion of chiral epoxides to acetoactetate [1-4]. The initial steps in 
the pathway involve the epoxidation of propylene followed by nucleophilic addition of 
the small cofactor coenzyme M to the R-and S-enantiomers of epoxypropane, resulting in 
a racemic mixture of R- and S-hydroxypropyl CoM (R- and S-HPC, respectively). R- and 
S-HPC are then converted into a common achiral product 2-ketopropyl-CoM (2-KPC) 
using two highly stereospecific dehydrogenases, (R)-hydroxypropyl-coenzyme M 
dehydrogenase (R-HPCDH) and (S)-hydroxypropyl-coenzyme M dehydrogenase (S-
HPCDH) (Figure 2-1). A remarkable feature of R- and S-HPCDH (40 % sequence 
identity) is the extremely high substrate stereospecificity exhibited by these enzymes 
(each enzyme displays less than 0.5% activity with the opposite substrate isomer [2]), 





Figure 2-1. R-HPCDH and S-HPCDH convert R-and S-hydroxypropyl CoM 
(R- and S-HPCDH) to a common product 2-ketopropyl-CoM (2-KPC). 
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R- and S-HPCDH have been characterized as members of the “classical” short-
chain dehydrogenase/reductase (SDR) superfamily of enzymes.  SDR enzymes are found 
throughout  eukaryotic and prokaryotic species and constitute one of the largest enzyme 
families known with over 60,000 members annotated in sequence databases [5]. SDR 
enzymes are categorized in several enzyme classes including lyases, isomerases, and 
oxidoreductases, and they act on a broad range of substrates including steroids, sugars, 
xenobiotics, and aliphatic alcohols [5-7]. Despite the relatively low sequence identity 
between SDR enzymes (15-30% sequence identity), structural studies have revealed a 
common scaffold that includes N- and C- terminal domains [8]. The N-terminal domain 
is a highly conserved Rossman-fold structure that contains a catalytic triad/tetrad (Tyr-
Lys-Ser-Asn in the case of R- and S-HPCDH) and a GxxxGxG motif involved in 
NAD(P)(H) binding . The C-terminal domain is more variable, both in terms of sequence 
and structure, but generally contains a substrate binding loop region that is involved in 
substrate binding and specificity [8-11].  Although numerous SDR superfamily enzymes 
exhibit stereospecificity, few stereospecific enzymes have been found to function in 
concert with a homologous partner-enzyme. R- and S-HPCDH represent an ideal model 
system to examine stereospecificity because they perform identical chemistry in the same 
pathway, yet both enzymes are highly specific for their respective substrates (R-HPC or 
S-HPC). 
 Several biochemical studies, and a product bound structure of R-HPCDH has led 
to a proposed mechanism for R- and S-HPCDH [12-16]. In this mechanism, the role of 
the catalytic tetrad residues (Tyr-Lys-Ser-Asn) and the chemistry around the chiral 
carbon (C2) is analogous to the general mechanism described for other SDR enzymes [6, 
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17]. Specifically, the catalytic tetrad serine assists in positioning the hydroxyl group of 
the substrate near the catalytic tyrosine. The tyrosine residue in its deprotonated form acts 
as a general base for proton abstraction from the substrate hydroxyl group, and a hydride 
is transferred from the C2 carbon of the substrate to NAD+.  Lysine has a dual role in 
coordinating NAD(H) and in lowering the pKa of the catalytic tyrosine hydroxyl group 
through a proton relay involving water molecules and the catalytic tetrad asparagine.  The 
product bound structure of R-HPCDH reveals a pair of positively charged amino acids 
(R152, R196) that coordinate the sulfonate tail of 2-KPC [16]. Kinetic analysis of S-
HPCDH mutants suggest that positively charged amino acids (R211 and K214) may also 
contribute to sulfonate binding in the S-enzyme [15]. It has been proposed that in each 
enzyme the sulfonate binding residues are used to properly orient the reactive groups of 
the substrate at the catalytic site [13, 15, 16]. Although a crystal structure of R-HPCDH is 
available, there are no structures of S-HPCDH. Furthermore, no substrate bound 
structures of R- or S-HPCDH are currently available. Here we report high-resolution 
binary (NAD+ bound) and ternary (S-HPC/NADH bound) complex crystal structures of S-
HPCDH. These structures provide insight into the structural architecture of the active site 
and substrate binding path of S-HPCDH. In addition, the structures allow for the first 
structural comparison between S-HPCDH and R-HPCDH, clarifying structural 






MATERIALS AND METHODS 
 
Expression, purification, and crystallization   
Three sequence variants of S-HPCDH exist on a single megaplasmid in 
Xanthobacter autotrophicus strain Py2 [18]. The most well behaved S-HPCDH variant in 
vitro (previously designated as S-HPCDH3) was expressed and purified in E. coli as 
previously described [15]. Protein was concentrated to 13 mg/ml in the presence of 25 % 
glycerol and stored at -80 °C. Protein was thawed on ice and crystallized by sitting drop 
vapor diffusion at 4 °C at a 1:1 protein:well drop ratio in a well solution consisting of 0.1 
M Bis-Tris, pH 6.5, 0.35M ammonium acetate and 27 % polyethylene glycol 3350. 
Crystals of S-HPCDH bound to NAD+ (binary complex) were grown in the presence of 
50 µM NAD+ and 50 µM S-HPC. The crystal was transferred directly into a 
cryoprotectant composed of the mother liquor, 50 µM S-HPC and 10 % glycerol, and 
flash-cooled in liquid nitrogen. S-HPC/NADH bound crystals (ternary complex) were 
grown in the presence of 50 µM NADH and 50 µM S-HPC. The crystal was transferred 
directly into a cryoprotectant composed of the mother liquor without ammonium acetate, 
140 µM S-HPC and 10 % glycerol, and flash-cooled in liquid nitrogen.  
 
Data collection  
Diffraction data were generated and collected using a home-source x-ray generator 
(Rigaku RU-200 and MicroMax-007HF) and detector (Rigaku R-AXIS IV++). Data were 
processed using the HKL2000 program suite [19]. The S-HPCDH crystals belong to space 
group P21212 with unit cell dimensions of a= 116 Å, b= 128 Å, and c= 58 Å. Data statistics 
are summarized in Table 2-1.  
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Structure determination, model building and refinement  
 
The binary complex S-HPCDH structure was solved by molecular replacement 
using the R-HPCDH structure ([16], PDB code, 2cfc) as a molecular replacement search 
model. The ternary complex structure was solved by molecular replacement using the 
refined binary complex as a search model. Molecular replacement was performed using 
Phaser [20] from the Phenix program suite [21].  
Manual building of the S-HPCDH structures was done using the program COOT 
[22]. Electron density maps were high in quality, permitting unambiguous identification 
and positioning of the majority of amino acids in each monomer of asymmetric unit. 
Discontinuous electron density prohibited modeling of the first two N-terminal amino acids 
in each monomer, and a loop region beginning at position 200 and extending to positions 
204-207, depending on the monomer. The one exception is one monomer in the ternary 
complex structure, in which the entire loop region is observed. Although S-HPC was 
included in the crystallization and cryo solutions for the NAD+ bound structure, no electron 
density was observed for S-HPC. Instead, an acetate molecule (originating from the 
crystallization buffer) was observed at the active site, essentially mimicking the position 
of the S-HPC reactive center. Refinement of the S-HPCDH structures were performed 
using phenix.refine [23] from the Phenix program suite [21]. Geometry statistics were 
calculated using MolProbity [24,25]. The refined coordinates and structure factors were 
deposited in the protein data bank under accession ID 4GH5 (binary complex) and 4ITU 




Table 2-1. Data collection and refinement statistics for S-HPCDH structures. Values in 








Data collection   
Wavelength (Å) 1.5418 1.5418 
Resolution range (Å) 35.0 - 1.60  35.0 - 1.60  
Outer shell (Å) 1.66 – 1.60 1.66 – 1.60 
No. of reflections   
     unique 113,574 108,385 
     total 708,549 1,179,096 
Average redundancy 6.2 (2.8) 10.9 (7.9) 
Mean I/(I) 25.8 (1.9) 37.0 (3.3) 
Completeness (%) 98.3 (86.0) 93.7 (63.9) 
Rsym (%)a 6.3 (38.9) 5.7 (37.4) 
Space group P21212 P21212 
# of protein molecules/ asym. unit 4 4 
Unit cell dimensions   
     a, b, c (Å) 116.1, 127.9, 58.5 116.0, 128.4, 58.4 
(°) 90.0, 90.0, 90.0 90.0, 90.0, 90.0 
Refinement   
Rwork/Rfree (%)b 17.1/19.9 16.4/19.5 
Atoms in the structure 8,114 8,098 
    protein 6,895 6,977 
    waters 1027 931 
    ligands 192 220 
Average B factor (Å2) 13.8 14.3 
    protein 12.5 13.2 
    water 22.5 23.4 
    NAD+/NADH 11.0 11.0 
    S-HPC --- 22.4 
rmsd bond (Å)/angle (°) 0.008/1.104 0.007/1.114 
Protein geometry c   
     Ramachandran outliers (%) 0 0 
     Ramachandran favored (%) 98.9 98.1 
     Rotamer outliers (%) 0 0.9 
PDB ID 4GH5 4ITU 
a  Rsym= (|(I-<I>)|)/(I), where <I> is the average intensity of multiple measurements. 
b Rwork = (|Fobs-Fcalc|)/(|Fobs|) and is calculated using all data; Rfree is the R-factor based 
on 5% of the data excluded from refinement. 






Overall structure of S-HPCDH   
The binary and ternary crystal structure of S-HPCDH both adopt nearly identical 
protein conformations (RMSD = 0.091 Å over 904 residues). The quaternary structure of 
S-HPCDH is a homo-tetramer (Figure 2-2), similar to the previously reported structure of 
R-HPCDH [16] and other SDR proteins [8]. The tetramer is assembled such that each 
subunit interacts with the other three subunits. As shown in Figure 2 (for clarity, subunit 
A is described, but analogous interactions are observed for each subunit in the tetramer), 
major interactions between subunit A and the other subunits include a four helix bundle 
between the long helices D and E of subunits A and C (Figure 2-2, box 1) and several 
hydrophobic interactions between the F helices of subunits A and B (Figure 2-2, box 2). 
An additional interaction is also observed at the N-termini of each subunit in which 
several water molecules are coordinated by R4 and Q237 from each subunit (Figure 2-2, 
box 3). A similar N-terminal interaction has not been observed in other SDR family 
structures including R-HPCDH, and to our knowledge is a unique feature of S-HPCDH. 
The tetramer is further stabilized by a crossover interaction between diagonally spaced 
subunits (subunits A and D in Figure 2-2, box 4).  This interaction involves adjacent C-
terminal carboxylate groups of I258, which coordinate two water molecules. A similar 









Each monomer of S-HPCDH has a bipartite domain structure with the active site 
located at the bottom of a cleft formed between the N- and C- terminal domains (Figure 
2-3). The large N-terminal domain comprises the core of the structure and is in the form 
of a NAD(H) binding Rossman-fold motif common to SDR enzymes [8]. The 
dinucleotide binding Rossman-fold found in all SDR enzymes is composed of a central 
twisted seven-stranded parallel -sheet (A-G) that is flanked on each side by three -
helices (A-F).  In S-HPCDH, D and E are located on the same side of the Rossman 
fold and are about twice the length of the other -helices, resulting in an overall N-
terminal domain with two -helices that are much longer on one side (Figure 2-3A). Two 
loops connect D and E to their respective -strands (D and E to D and E, 
respectively), and these long loops constitute one side of the active site cleft.  
 
Figure 2-2. Tetrameric structure of S-HPCDH. Each subunit of S-HPCDH (labeled a-d) 
interacts directly with each of the other three subunits. Direct interactions between 
subunit a and the other three subunits are indicated with boxes labeled 1-4. 
  
Figure 2-3. Monomeric structure of S-HPCDH. (A) Cartoon representation of one of the monomers of S-HPCDH ternary complex.  
The N- terminal Rossman fold domain is depicted with β strands colored red, loops colored green, and α-helices colored green. The C-
terminal domain is colored yellow. NADH (pink) and S-HPC (gray) molecules are shown as sticks. The region spanning helices FF1 
and FF2 is commonly referred to among SDR enzymes as the substrate binding loop. (B) Catalytic site of S-HPCDH ternary 
complex. S-HPC is bound with its reactive OH group coordinated between S143 and Y156. The sulfonate tail of S-HPC is 
coordinated by T188, R211 and Y215. Water molecules that contribute to a proposed proton relay are shown as red spheres. (C) A 
2Fo-Fc omit map surrounding S-HPC and NADH in the ternary structure, contoured at 1 .                                                                                          
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 The last several C-terminal residues (following G) and an extensive loop 
inserted between F and F fold into a small C-terminal domain. The C-terminal domain 
contains two additional -helices (FF1, FF2) that protrude upward forming two sides 
of a lobe and the other side of the active site cleft. This lobe is referred to as the substrate 
binding loop, following the nomenclature employed for other SDR enzymes [9-11]. In 
the SDR superfamily, the substrate binding loop exhibits a high degree of sequence 
variation between proteins and often contains residues important for substrate binding 
[11].  In the S-HPCDH structure, R211 and K214 (which have been implicated in 
substrate binding) are both located on FF2 (Figure 2-3B). The residues connecting 
FF1 to FF2 (amino acids 200-204) are observed in one monomer of the ternary 
complex, but appear to be somewhat flexible as indicated by high b-factors and 
discontinuous electron density for the rest of the monomers in the ternary structure and 
all of those in the binary structure.   
 
Active site and substrate binding  
The active site of S-HPCDH is located in a cleft between the N- and C-terminal 
domains (Figure 2-3). In both the binary and ternary structures, NAD+/NADH bind S-
HPCDH in an extended conformation along an axis parallel to a plane created by the C-
termini of the central β-sheet. Specific protein interactions are consistent with NAD(H) 
binding observed in R-HPCDH and other SDR enzymes [7, 16]. In contrast with the R-
HPCDH structure, strong electron density is observed for all copies of the entire 
NAD+/NADH molecule, including the nicotinamide ring (Figure 2-3C), with average b-
factors of 11.0 Å2 for each complex. Since the crystallization experiments for both the 
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binary and ternary complexes were performed aerobically, it is possible that NADH was 
oxidized to NAD+, which could be difficult to distinguish at 1.6 Å resolution. If NAD+ 
were present at the active site of the ternary complex (which was co-crystallized with S-
HPC and NADH), then we would expect a reaction to proceed converting S-HPC to 2-
KPC. However, S-HPC is clearly observed within the active site of the ternary structure, 
suggesting that NADH rather than NAD+ is bound. 
In the ternary complex, S-HPC binds in a pocket that extends from above the 
nicotinamide ring of NADH toward FF2 of the substrate binding loop (Figure 2-3B). 
Each of the four S-HPC molecules is well ordered along its entire length (Figure 2-3C) 
with average b-factors of 22.4 Å2. The sulfonate tail of S-HPC is coordinated by T188, 
R211 and Y215 (Figure 2-3B). K214 is also located near the sulfonate tail, but electron 
density for the terminal side chain atoms is weak and no direct interaction is observed. 
One side of the S-HPC binding pocket is entirely composed of residues located on FF1 
(M194, G195, L198, and L199), and the other side of the pocket is composed of 
hydrophobic residues (V144, A145 and I150) provided by the N-terminal domain. On the 
reactive end of the S-HPC molecule, the OH group is coordinated by direct interactions 
with the S143 and Y156 side chains. This orientation places the chiral center of S-HPC 
directly above the nicotinamide ring of NADH (Figure 2-3B,C).  
The observed orientation of S-HPC, NADH and the catalytic tetrad (Y156, K160, 
S143, N115) in the ternary complex is consistent with the catalytic mechanism described 
for other SDR enzymes [6, 17]. Specifically, the general acid/base Y156 is positioned 
between S143 and K160, with its catalytic hydroxyl forming  hydrogen bonds with the 2’ 
hydroxyl of the ribose ring of NADH  and the OH group of S-HPC (Figure 2-3B). The  
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amino group of K160 forms a bidentate hydrogen bond with the 2’ and 3’ hydroxyl 
groups of the nicotinamide ribose. A water molecule is also observed to be coordinated 
between N115 and K160. This water molecule is further coordinated to a string of other 
waters, suggesting a proton relay chain connecting the bulk solvent to the active site 
tyrosine using N115, K160 and NAD(H) as has been proposed for other SDR family 
enzymes [6, 27, 28]. Notably, no conformational differences are observed between binary 
and ternary structures for the catalytic tetrad side chains or the residues surrounding the 
S-HPC binding site, with the exception of R211.This observation suggests that the 
substrate binding pocket is fully configured for S-HPC binding once NAD(H) is bound, 
and may be consistent with an ordered binding mechanism for S-HPCDH. 
 
Structural comparison of S-HPCDH and R-HPCDH  
The overall structure of S-HPCDH is highly homologous to the R-HPCDH 
structure and other SDR family enzymes. The arrangement of the catalytic tetrad is 
superimposable between the R- and S- enzymes (RMSD=0.24 Å). However, 
superposition of the R-HPCDH and S-HPCDH structures reveals three regions within 
each monomer that display different structural conformations: a small shift in the C-
terminal end of αB and two larger conformational rearrangements in the substrate binding 
region above the active site (Figure 2-4A, B). The shift observed in αB does not appear to 
impact the structure of the active site or the substrate binding region, and likely has no 
functional consequence. The larger rearrangements directly impact the substrate binding 
region and are each centered around a three amino acid insertion/deletion located on a 
loop connecting Dand D, and on a loop connecting FF1 and FF2. 
 Figure 2-4. Structural differences between R-HPCDH and S-HPCDH. The largest differences center around 3-residue insertions 
within each enzyme. Insertions are indicated by ψ in R-HPCDH and by * in S-HPCDH.  (A) Superposition of R-HPCDH (gray) and S-
HPCDH (green). Sites of major structural differences are indicated with boxes. (B) Top view (as compared to view in panel (A)) of 
superimposed R- and S-HPCDH structures. Bound molecules (S-HPC in S-HPCDH and 2-KPC in R-HPCDH) are shown as sticks. 
Carbon atoms are colored green for S-HPC and gray for 2-KPC (C) View of the 3-residue insertion in R-HPCDH (N93, S94, E95), 
and binding of the product 2-KPC at the active site. The backbone carbonyl oxygen atom for N93 is also shown.  (D) View of the 3-
residue insertion in S-HPCDH (S201,D202,T203) and binding of the substrate S-HPC at the active site. The backbone carbonyl 
oxygen atoms for L199 and D202 are also shown. (E) Sequence alignment of R- and S-HPCDH. Identical residues are shaded orange; 
similar residues are shaded yellow. The positions of the 3-residue insertions are indicated as ψ in R-HPCDH and * in S-HPCDH. 
Sulfonate binding residues and catalytic tetrad residues are indicated with diamonds. Residues that contribute to the methionine switch 





Repositioning of the loop between D and D results from a loss of three amino acids in 
S-HPCDH (Figure 4E). In the R-HPCDH structure, these three residues (N93, S94, and 
E95) flank the entrance of the substrate binding pocket, and the main chain carbonyl 
oxygen from one of the residues (N93) forms a hydrogen bond to the amide nitrogen of 
R152 (Figure 4C).  R152 is one of two arginine residues used by the R-enzyme to bind 
the sulfonate tail of endogenous substrates and the product 2-KPC [13, 16]. The deletion 
of these three residues in S-HPCDH collapses and reconfigures this substrate binding 
region such that the binding pocket found in R-HPCDH is lost. 
Conversely, three amino acids (residues S201, D202, and T203) are inserted in 
the loop between FF1 and FF2 in S-HPCDH (Figure 4D, E). Although the loop 
appears to be mobile in the crystal (weak electron density prevented complete modeling 
of the loop in 3 of 4 monomers in the ternary structure), the net effect is an opening up of 
the space between FF1 and FF2, as compared to R-HPCDH (Figure 4A, B). The 
increased separation between FF1 and FF2, combined with amino acid substitutions 
in the surrounding region, facilitates formation of a new substrate binding pocket. Main 
chain carbonyl oxygen atoms (L199 and D202) from the loop between FF1 and FF2 
help orient R211 for S-HPC sulfonate binding through water mediated hydrogen bonds in 
a manner analogous to the loop stabilization of R196 observed in the R-HPCDH substrate 
binding pocket. 
While the three residue insertions/deletions play the most dramatic role in 
reconfiguring and repositioning the substrate binding pockets of R- and S-HPCDH, other 
sequence differences throughout the region also contribute. Most notably is a 













R152 of R-HPCDH. Conversely, M187 in R-HPCDH replaces the sulfonate binding 
residue T188 of S-HPCDH. In each case, the methionine residue creates a steric block 
that closes off the path to the sulfonate binding site observed in the other enzyme (Figure 
2-5). The net effect of all these amino acid substitutions and structural rearrangements is 
the formation of two distinct substrate binding pockets that are rotated by approximately 
60 with respect to each other (Figure 2-5). In each case, the pocket contains residues that 
can bind the sulfonate moiety at the distal end of the substrate, which differentially 





R-and S-HPCDH represent a rare set of stereospecific enzymes that both function 
in a single metabolic pathway to produce the same product from different enantiomeric 
Figure 2-5. Distinct substrate binding pockets are observed in R-HPCDH- and S-
HPCDH. (A) Sliced view of S-HPCDH bound to the substrate S-HPC. The shape of the 
substrate binding pocket is outlined in green. (B) Sliced view of R-HPCDH bound to the 
product 2-KPC. The shape of the substrate binding pocket in R-HPCDH is outlined in 
orange. (C) Superimposed outlines of the two substrate binding pockets highlights the 
distinct shape and directionality of the distal ends of each substrate binding pocket 
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substrates. This provides an ideal system for understanding mechanisms of 
stereospecificity. Previous biochemical studies have shown that stereochemical 
discrimination is governed by different kinetic parameters in each enzyme [15]. 
However, a structural understanding of this system has been limited because only the R-
HPCDH structure was available [15, 16]. 
In order to more completely understand the structural mechanisms used to achieve 
stereospecificity we have now determined the crystal structure of S-HPCDH. It was 
previously proposed that specificity of R- and S-HPCDH is controlled in large part by 
alternative locations of sulfonate binding residues in each enzyme [13, 15, 16]. In the 
current S-HPCDH structure we confirmed that there was alternative placement of 
substrate sulfonate binding residues when compared to sulfonate binding residues in the 
R-HPCDH structure. Not foreseen, however, was how sequence variations within the 
active site cleft of R- and S-HPCDH provide each enzyme with distinct substrate binding 
pockets. Significantly, the unique arrangement of these stereospecific pockets doesn’t 
appear to arise through a simple inversion of the active site. Rather, each pocket adopts 
unique shape and binding characteristics at the site of sulfonate binding (Figure 2-5C). 
To visualize how the specific shape and orientation of the substrate binding 
pocket in S-HPCDH affects specificity, we modeled R-HPC into the S-HPC binding 
pocket of S-HPCDH (Figure 2-6).  Effective catalysis for either substrate (S-HPC or R-
HPC) requires that the C2 (chiral carbon) hydroxyl group is positioned for proton 
abstraction between S143 and Y156, and the C2 hydrogen is pointed towards the b-face 
















ternary complex, the C2 methyl group of S-HPC is positioned within an open region of 
the substrate binding pocket where it is free of steric hindrance (Figure 2-6A). In contrast, 
when R-HPC is modeled into the catalytic site in the same fashion, the C2 methyl group 
of R-HPC is oriented directly toward the wall of the substrate binding pocket, resulting in 
significant steric clashes with the side chain of the catalytic serine (S143) (Figure 2-6B).  
This observation is consistent with the 290-fold increase in Km observed when R-HPC is 
used as a substrate for S-HPCDH [15], and provides a structural basis for 
stereospecificity displayed by S-HPCDH. 
In summary, several strategies are employed by the R- and S- HPCDH system to 
achieve stereospecificity. The enzymes utilize a common catalytic site but reorient the 
Figure 2-6. S-HPC and a model of R-HPC within the active site of the S-HPCDH ternary 
complex. Both substrates are shown with their C2 hydroxyl group and C2 hydrogen 
atoms oriented for effective catalysis. The C2 carbon is indicated with an asterisk (*).  
Residues within the active site are displayed with carbon atoms colored green. Carbon 
atoms of NADH are colored pink. The surface of the substrate binding pocket is shown as 
a gray line. (A) The C2 methyl group of S-HPC is spatially accommodated within the 
active site. (B) When R-HPC is properly aligned for catalysis, the C2 methyl group is 
directed toward the pocket wall and clashes directly with S143. Insert depicts the 
potential clash of the C2 methyl group of R-HPC with S143 of S-HPCDH. The molecular 
surface of the methyl group carbon atom (C1) of R-HPC and the side chain oxygen atom 
of S143 are shown as dot representation. 
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substrate binding path as it moves away from the active site. Reorientation of the binding 
path is achieved by a three residue insertion/deletion and alternately expands or collapses 
the binding pocket and assists in coordinating the distal end of the substrate. Additional 
mutations that include a methionine switch further modulate access to and the shape of 
the substrate binding path. These strategies may provide a basis for rational design of 
stereospecificity in other systems.  
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INTRODUCTION II: AIR PROTEINS AND RNA REGULATION 
 
In eukaryotes, RNA levels and RNA quality are tightly regulated 
Eukaryotic cells produce a multitude of different types of RNA. In addition to 
protein-coding mRNA, the transcriptome is also comprised of many non-coding RNAs 
including transfer RNAs (tRNA), ribosomal RNAs (rRNA), small nuclear and nucleolar 
RNAs (snRNA and snoRNA), cryptic unstable transcripts (CUT’s), and intergenic 
sequences (introns) [1-3]. Most of these non-coding RNAs have direct regulatory roles in 
gene expression and translation. After transcription most if not all RNAs are subject to a 
variety of maturation events to become fully functional RNAs. These posttranscriptional 
modifications often first involve folding of the RNAs into intricate three dimensional 
structures, followed by a variety of processing steps such as internal cleavage, end 
trimming, and covalent modifications.  The cellular levels and quality of RNAs produced 
in the cell must be constantly monitored and controlled in order to ensure proper cell 
function and survival. In humans, defects in RNA processing and regulation have been 
linked to many disease states including neurodegenerative diseases and cancer [4-6], 
highlighting the importance of understanding the biological mechanisms controlling 
RNA maturation and stability. 
In the nucleus of eukaryotic cells RNA biogenesis and stability is regulated by 
RNA quality control and surveillance pathways. These pathways are comprised of a 
variety of molecular machines including ribonucleases, RNA binding proteins, and many 
others, which ensure that only properly processed RNAs are stabilized and all other non-
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functional RNAs – including aberrantly processed RNAs and end-trimmings – are 
degraded. In yeast, the nuclear TRAMP complex is required for RNA surveillance and 3’ 
maturation of many RNAs [7-10]. TRAMP is a three-protein complex composed of an 
RNA binding protein (Air1 or Air2), a RNA helicase (Mtr4) and a RNA poly(A) 
polymerase (Trf4 or Trf5). Together these proteins identify particular RNAs, and 
stimulate their degradation via the 3’-5’ exonuclolytic activities of the RNA exosome, the 
primary RNA degrader in the nucleus. 
Intricate to TRAMP function are the RNA binding proteins Air1 and Air2 
(collectively referred to as Air proteins). The Air proteins are the identifiers of a myriad 
of RNA species that are targeted for decay, and they have also been shown mediate 
crucial protein-protein interaction within TRAMP [11-13]. In addition to their function 
within TRAMP, the Air proteins have also been implicated in regulating the activity of 
other proteins that are involved in nuclear mRNA transport [14]. In this role, the Air 
proteins may serve a function in RNA quality control by regulating the quality of mRNA 
transcripts that are exported to the cytoplasm. Although it is known that the Air proteins 
are involved in these various processes, details of how they interact with other proteins 
and RNA is lacking. The research presented in the last portion of this dissertation 
(Chapters 4-6) aims to further the understanding of Air protein functionality, with 






The RNA Exosome is required for RNA degradation  
In eukaryotes, a multi-protein complex called the RNA exosome serves the 
primary role of 3’-5’ RNA degradation in the nucleus and cytoplasm. Essential functions 
performed by the exosome include 3’-5’ end-processing of nuclear RNA precursors such 
as rRNAs, sn(o)RNAs, and tRNAs, turnover of both non-coding RNA in the nucleus and 
protein-coding mRNA in the cytoplasm, and RNA surveillance - where many types of 
aberrant non-functional RNAs are identified and degraded [8, 9, 15-21]. Crystal 
structures of the exosome from eukaryotes and archaea reveal a conserved structural 
architecture throughout species. The exosome is composed of a nine-subunit core (EXO-
9).  Six of these subunits are RNase PH domain containing proteins that form a 
hexameric barrel-like structure with a central channel.  The other three subunits contain 
S1/KH RNA binding domains that assemble into a trimer that caps one side of the barrel-
like hexamer, forming an entry pore to the central channel [22-24]. This EXO-9 core is 
conserved in eukaryotes and archaea. However, in contrast to the archaeal exosome, in 
eukaryotes the RNase PH domain proteins that comprise EXO-9 have apparently lost 
activity during evolution [23, 24], and nucleolytic activity is instead attained by 
association with additional proteins. In S. cerevisieae, the EXO-9 core associates with the 
endo- and 3’-5’ exo-ribonuclease Rrp44 (Dis3) to form the catalytically active EXO-10 
complex, which functions in both the nucleus and cytoplasm [25]. Structural analyses 
have shown that the Rrp44 nuclease associates near the bottom of the exosome core on 
the opposite side from the trimeric cap.  In this position, unstructured ssRNAs can thread 
through the narrow entry pore (10-12 Å across) and into the central channel of the core to 
meet the exonucleolytic site of Rrp44 [25, 26]. In the nucleus, EXO-10 also associates 
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with the non-essential 3’-5’exoribonuclease Rrp6 to form the EXO-11 complex [27]. 
Rrp6 binds to the exosome trimeric cap and is required for particular degradation 
functions, such as processing of 5.8S rRNA and distinct processing events of sn(o)RNAs 
[28-30]. 
 
The RNA exosome requires cofactors 
The functional exosome requires additional proteins, collectively called exosome 
co-factors, to stimulate its activity and substrate specificity in vivo [31]. The requirement 
of protein cofactors is not well understood, but likely involves specific recognition of 
RNA substrates and providing an unstructured 3’ end suitable for exonucleolytic 
degradation. In S. cerevisiae the major exosome-activating cofactors include two related 
DExH-box helicases Mtr4 and Ski2 and their associated proteins. Ski2 is found only in 
the cytoplasm where it associates with two putative RNA binding proteins Ski3 and Ski8 
to form the physiological multimeric SKI complex [23, 32]. In the cytoplasm the SKI 
complex is required for mRNA surveillance and mRNA turnover by EXO-10. The 
DExH-box helicase Mtr4 is strictly nuclear, and unlike Ski2, Mtr4 has some independent 
functions such as the processing of 5.8S rRNA [27, 33-35]. Mtr4 is also found in a 
physiological protein complex called TRAMP, which in addition to Mtr4 contains a RNA 
binding protein (Air1 or Air2) and a RNA poly(A) polymerase (Trf4 or Trf5). In budding 
yeast, TRAMP is essential and required for nuclear RNA surveillance and processing by 





The TRAMP complex is required for nuclear RNA surveillance and processing 
 The Trf4/5-Air1/2-Mtr4-Polyadenylation complex (TRAMP) of S. cerevisiae was 
discovered independently by three different groups in 2005 [9, 31, 36].  These initial 
studies indicated that TRAMP is composed of the DExH box RNA helicase Mtr4, a 
poly(A) polymerase Trf4, and one of two paralogous zinc knuckle proteins Air1 or Air2 
(45% sequence identity). Later studies indicated that another TRAMP complex is formed 
by a Trf4 paralog Trf5 (48% sequence identity), which only associates with Air1. Thus, 
two types of TRAMP complexes are thought to exist. TRAMP4 contains Mtr4, Trf4, and 
either Air1 or Air2, and TRAMP5 contains Mtr4, Trf5, and only Air1. The duplicated Air 
and Trf genes likely arose during a whole genome duplication event in S. cerevisiae 
about 100 million years ago [37, 38], and therefore other eukaryotes have only one 
ortholog of each. In humans, the Air and Trf orthologs are named ZCCHC7 and PAPD5, 
respectfully. Furthermore, ZCCHC7 and PAPD5 have been shown to form a trimeric 
complex with human Mtr4 (hMtr4) [39], suggesting conservation of the TRAMP 
complex between fungi and animals.  
TRAMP directly stimulates the nuclear exosome for processing and degradation 
of many types of RNA including tRNAs, sn(o)RNAs, rRNAs, pre-mRNAs,  CUTs 
(cryptic unstable transcripts), and a number of intergenic transcripts [7-10]. In the current 
model of TRAMP function (Figure 3-1), Air1/2 identifies particular RNA substrates, 
Trf4/5 adds a short (~4-5 nt) poly(A) tail to the 3’ end of the RNA, and Mtr4 unwinds 
any RNA secondary structure that may exist [9, 31, 36, 40, 41]. This unwinding and 
polyadenylation by TRAMP is presumed to provide an unstructured single stranded 3’ 

















Interestingly, the function of polyadenylation by TRAMP is in contrast to the 
traditionally described function of polyadenylation by canonical poly(A) polymerases 
(PAPs). In eukaryotes, polyadenylation by PAP stabilizes pre-mRNAs, and requires 
recognition of specific sequence elements on the pre-mRNA transcript [42]. On the other 
hand, TRAMP polyadenylation stimulates RNA degradation, and TRAMP substrates 
have no identifiable similarities in sequence, structure, or function. [40, 41, 43]. After the 
initial discovery of TRAMP, a central question was how polyadenylation by PAP 
stabilizes RNA, while polyadenylation by TRAMP targets RNA for destruction?  Recent 
Figure 3-1. Tramp mediated RNA degradation by TRAMP4 (Trf4, Air2, 
and Mtr4). The TRAMP complex identifies RNAs, adds a short 3’ poly(A) 
tail (4-5 nt), and stimulates their degradation by the nuclear exosome. 
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reports have revealed the likely answer to this question. The key difference governing the 
fate of polyadenylated RNA is likely attributed to a marked difference in the length of the 
3’ poly(A) tail. The oligo(A) tails appended by PAP are typically several dozen to 
hundreds of nucleotides long [44]. Recent data has indicated that the length of oligo(A) 
tails appended by TRAMP peaks at 4-5 nucleotides [8]. During pre-mRNA maturation, 
addition of at least 12 adenosines are required for binding of the canonical poly(A) 
binding protein Pab1, which serves in part to stabilize nuclear mRNA [44]. TRAMP 
oligo(A) tails are apparently too short for Pab1 binding, and as a result are left 
unprotected and subject to degradation by the exosome [8].   
 
The non-canonical Poly(A) polymerases Trf4 and Trf5 
 Trf4 was originally identified in a synthetic lethal screen with DNA 
topoisomerase I (Top1) mutants, and hence was given the name Topoisomerase I related 
function 4 protein. Further genetic studies identified the Trf4 paralog Trf5 (48% sequence 
identity) [45]. Neither Trf4 nor Trf5 are individually essential. However, a Trf4Δ Trf5Δ 
double mutant is synthetically lethal [45, 46]. Homologues of Trf4 and Trf5 have been 
reported throughout eukaryotes including Cid14 in Sz. Pombe, and PAPD5 in humans 
[39, 47, 48].  
 Trf4 and Trf5 are members of the Cid1-family of non-canonical poly(A) 
polymerases. Members of the Cid1-family share common features with the canonical 
PAP, such as a homologous catalytic domain (NTP transferase domain) and central 
domain (PAP-associated domain) [47]. However, unlike the canonical PAP, most Cid1-
family members lack a recognizable RNA recognition motif (RRM) used to identify and 
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bind RNA substrates. To compensate for lack of an RRM, many Cid1 family members 
are presumed to employ additional RNA-binding proteins to target their substrates for 
polyadenylation [47], such as Air1 and Air2 homologues in yeast and humans. 
Accordingly, the presence of either Air1 or Air2 is required for the polyadenylation 
activity of Trf4 in vitro, and Air1Δ Air2Δ cells exhibit loss of polyadenylation of non-
coding RNAs in vivo [9, 31, 36]. 
    
The zinc knuckle proteins Air1 and Air2 
 In the TRAMP complex, Air1 and Air2 are involved in protein-protein and 
protein-RNA binding interactions. The various binding interactions of Air1 and Air2 and 
the implications of their binding interactions are the focus of this dissertation. The Air 
proteins were originally identified in a two-hybrid screen as proteins that could interact 
with the yeast arginine methyl transferase Hmt1, and were thus given the name Arginine 
methyltransferase interacting ring finger proteins [14]. Air1 and Air2 are paralogs that 
each contain five adjacent CCHC-type (C-X2-C-X4-H-X4-C) zinc knuckle motifs (also 
referred to as ring fingers) located between extended N- and C-terminal sequences 
(Figure 3-2). The Air proteins contain 45% sequence identity with the majority of identity 
conserved in the region comprising the zinc knuckles (68% sequence identity).  Zinc 
knuckle motifs (ZnKs) are cysteine rich sequences that structurally fold into reverse turns 
to coordinate a zinc metal ion using three cysteine residues and one histidine. ZnKs were 
initially characterized in retroviral nucleocapsid proteins where they are used for binding 
ssRNA [49]. Many ZnK proteins have also been found throughout eukaryotes from yeast 
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Figure 3-2. Air1 and Air2 sequence alignment. Identical sequences are colored orange. 
Semi-conserved sequences are colored light yellow. Zinc knuckles (ZnKs) are indicated 
by green boxes and ZnK residues are indicated by black triangles 
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The Air proteins provide RNA binding in TRAMP  
Since the initial discovery of TRAMP, the zinc knuckles of Air1 and Air2 have 
been presumed to function as the RNA binding component of the complex. This idea was 
first made evident in mutagenesis experiments which showed that polyadenylation of an 
aberrant form of a structured RNA (tRNAAla) by a Trf4-Air2 complex was significantly 
impaired upon deletion of the three most N-terminal ZnKs of Air2 [12]. This result 
correlated with previous experiments (described above) that indicated Air1 and Air2 are 
required for Trf4 polyadenylation of RNAs, including polyadenylation of the structured 
precursor-RNA hypomodified tRNAiMet [9, 13, 31, 36]. Notably, hypomodified tRNAiMet 
is the most well characterized RNA substrate of TRAMP.  Recent reports have further 
clarified the involvement of Air2 ZnKs in binding aberrant forms of structured RNAs. In 
2012, Holub et al. used NMR studies to reveal that binding of hypomodified tRNAiMet by 
Air2 involved the second, third, and fourth ZnKs [13]. In that same report, fluorescence 
anisotropy experiments showed that an Air2 truncation mutant containing all five ZnKs 
could bind directly to an unstructured 12 nucleotide poly(A) oligo with a Kd in the low 
micromolar range, suggesting that Air2 ZnKs also bind unstructured RNAs.  
 
Air1 and Air2 provide substrate specificity in TRAMP   
In S. cerevisiae, TRAMP4 and TRAMP5 have been shown to have different sub-
nuclear localizations. For example, GFP-fusions of Trf4 and Air2 show that TRAMP4 
can be found throughout the nucleus, whereas GFP-fusions of Trf5 and Air1 are primarily 
enriched within the nucleolus [11, 50, 51], which is the site of rRNA maturation. 
Likewise, Trf5 has been shown to preferentially stimulate degradation of abarrent rRNA 
58 
precursors [52]. This compartmentalization of TRAMP5 could be explained by distinct 
substrate specificities between TRAMP complexes provided by either the Trf or Air 
components. Because the Air proteins have been shown to be the likely source of 
TRAMP RNA binding, they are also the likely source governing TRAMP RNA 
specificity [11, 13]. Indeed, a report by Schmidt et al. identified that Air1 and Air2 
govern TRAMP substrate specificity for vast number of different RNA types [53]. In that 
study a combination of genetic and deep sequencing techniques revealed that both of the 
Air proteins have overlapping function in directly stimulating the polyadenylation and 
degradation of most types of identified TRAMP substrates, including many rRNAs, 
sn(o)RNAs, CUTs, and mRNAs. In addition, the analysis also identified some differences 
in specificity between Air1 and Air2. For example, Air2 is independently involved in 
stimulating polyadenylation and degradation of several snoRNAs and spliceosomal 
RNAs, as well as regulating levels of some mRNA transcripts which code for enzymes 
involved in iron and carbon metabolism. Air1 was also shown to be independently 
involved in regulating levels of certain mRNAs which code for proteins involved in copy 
number control and regulation of the 2µ plasmid found in most yeast strains. Moreover, 
the study by Schmidt et al. made clear that the Air proteins are key for providing 
substrate specificity in TRAMP and the RNA exosome. However, the question of how 
characteristic differences between Air1 and Air2 might control differences in specificity 





Air1 and Air2 mediate protein-protein interactions in TRAMP 
A central question of TRAMP function has been how the three protein subunits 
associate with one another to form a functional complex. Initial studies of TRAMP 
indicated that Air2 and Trf4 form a tight complex in vitro.  However, identification of the 
binding interactions between the two proteins remained elusive until five years later. In 
2010, a crystal structure of a minimal Air2-Trf4 heterodimer revealed the binding 
interface between Air2 and Trf4 [12]. The crystal structure exhibits only the catalytic and 
central domains of Trf4 and the last two zinc knuckles of Air2 (Figure 3-3). In the model, 
the last zinc knuckle of Air2 (ZnK5) and sequences within the linker between ZnK4 and 
ZnK5 (L4) form direct interactions with the central domain of Trf4. Additional studies 
have also shown that recombinant Air2 with mutations in L4 or ZnK5 failed to co-purify 
and activate Trf4 [11, 13], indicating that the binding regions observed in the crystal 
structure represent the minimal binding interface between Air2 and Trf4. In addition, 
ZnK5 is the most conserved zinc knuckle amongst Air2 homologues, and the L4 binding 
residues constitute a conserved motif IWRxYxL, found in all Air2 homologues [11, 13]. 
The Air2 binding surface of Trf4 is also conserved in all Trf4 homologues. These 
observations suggest that the Air2-Trf4 binding interface observed in the crystal structure 
is phylogenetically conserved across species. 
Identifying how Mtr4 associates with the Air2-Trf4 has proven to be more 
difficult, and therefore Mtr4 protein-protein interactions within TRAMP remain poorly 
characterized. Part of the complexity of identifying protein-binding interactions with 
Mtr4 is due to the instability of recombinant Trf and Air proteins that contain extended 
























Figure 3-3. Crystal structure of a fragment of Air2 with the core domains of Trf4 (PDB 
id: 3NYB). (A) Domain organization of Trf4 and Air2. For Trf4 (1-584 aa), the catalytic 
domain (161-189, 316-481 aa) is colored grey. The central domain is colored light 
yellow. For Air2 (1-301 aa), Zinc knuckles are indicated by green boxes, Trf4 binding 
motif IWRxYxL in linker 4 (L4) is indicated by purple lines. Insert box shows sequences 
of Air2 ZnK4-ZnK5 with a dashed line indicating residues not observed in the crystal 
structure. (B) Cartoon ribbon diagram of the minimum Air2-Trf4 heterodimer. Protein 
domains are colored as in panel A. In Air2, zinc ions are shown as orange spheres and 
Trf4 binding residues in L4 are colored purple. 
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publication indicated that the N-terminus of Air2 is required to co-immunoprecipitate 
Mtr4 with an Air2-Trf4 heterodimer, suggesting that Air2 may also facilitate binding to 
Mtr4. In Chapter 5 of this dissertation I identify and characterize binding between a small 
peptide fragment of Air2 and Mtr4, revealing a binding interaction used by Air2 to bridge 
the three protein subunits of TRAMP. 
 
Air proteins are regulators of the methyltransfease Hmt1 and mRNA export. 
As mentioned previously, the Air proteins were initially identified as proteins that 
interact with the yeast arginine methyltarnsferase Hmt1 [14]. In that study, Air1 and Air2 
were shown to directly bind Hmt1 in yeast two- hybrid assays in which the RGG-box 
domain of the mRNA transport protein Npl3 was used as bait. The RGG-box domain of 
Npl3 is both a site used for binding mRNAs that are shuttled to the cytoplasm, and a site 
of methylation by Hmt1. In budding yeast, nuclear export of Npl3, and thus export of its 
mRNA cargo, requires methylation by Hmt1. Furthermore, Air1 was shown to inhibit 
Hmt1 methylation of Npl3 in vitro and in vivo, suggesting that binding of Air1 to Hmt1 
inhibits methylation, and thus inhibits mRNA export. To verify this model in vivo, Npl3 
and mRNA localization was analyzed in S. cerevisiae strains containing single gene 
deletions of Air1 and Air2, and Air1Δ Air2Δ double mutant strains. The single gene 
deletions had no observable effect on cell viability or Npl3/RNA transport. However, 
double mutant strains had a severe growth defect, suggesting some functional overlap of 
Air1 and Air2. The double mutant strain also exhibited nuclear retention of Npl3 and 
accumulation of Poly(A) mRNAs in the nucleus. Collectively these experiments 
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indicated that indeed the Air proteins can regulate methylation activity of Hmt1 and 
influence nuclear mRNA transport.  
Modification of proteins by arginine methylation serves many critical functions. 
For example, in eukaryotes arginine methylation is involved in RNA processing, 
transcriptional regulation, signal transduction, and DNA repair [54]. Currently, Air1 is 
the only known protein that has been demonstrated to regulate the activity of arginine 
methylation in S. cerevisiae. Understanding the mechanistic details of Hmt1 regulation 
would provide valuable insight to how arginine methylation is regulated endogenously. In 
Chapter 6 of this dissertation I describe my own research efforts aimed at understanding 
the interaction between the Air proteins and Hmt1, and also outline future directions for 
that research.   
 
The DExH-box helicase Mtr4 
The RNA helicase Mtr4 was first identified in a yeast genetic screen for 
identifying mutants that accumulate Poly(A) RNA in the nucleus. At that time, it was 
presumed that the accumulated poly(A) RNAs were mRNAs, and therefore the name 
mRNA transport 4 was given [55]. Mtr4 was the first characterized exosome co-factor, 
and current knowledge indicates that Mtr4 and its homologues (including other Ski2-like 
helicases) are required for all known exosome functions in vivo. Mtr4 homologues and 
associated protein complexes have been identified across species from fungi to humans.  
In S. cerevisiae Mtr4 can function independent of other proteins to stimulate the 
exosome, such as 5.8s rRNA processing [27, 33-35]. However, the majority of 
characterized functions of Mtr4 are in the context of the TRAMP complex. Like other 
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Ski2-like helicases, Mtr4 has 3’-5’ unwinding activity and RNA dependent ATPase 
activity. It is generally presumed that the helicase function of Mtr4 is used to prepare 
RNA substrates for exosome degradation by unwinding RNA secondary structure and 
displacing bound proteins from ribonucleoprotein complexes. 
Crystal structures of Mtr4, including apo and RNA-bound forms have provided 
insight into Mtr4s domain architecture and RNA binding path (Figure 3-4) [34, 56]. 
Similar to other Ski2-like helicases, Mtr4 has a four-domain helicase core that is 
composed of two canonical RecA-like folds (domains 1 and 2), a winged helix domain 
(domain 3), and a helical bundle domain, also referred to as the ratchet helix domain 
(domain 4). A large 256 amino acid insertion (arch domain) is also observed to be 
inserted into the winged helix domain.  The arch domain is a prominent feature that rises 
above the helicase core and terminates in a globular structure called the fist (also called  
the KOW domain) [34, 56]. The arch domain is unique to Mtr4 and other Ski2-like RNA 
helicases. Notably, in Mtr4 the arch domain is not required for helicase activity or 
binding to Air2-Trf4, but is required for 5.8S rRNA processing in vivo and binding 
tRNAiMet  in vitro [34, 56]. In all DExH-box helicases, the RecA1 and RecA2 domains 
contain conserved sequence motifs for binding and hydrolysis of ATP, a requirement for 
helicase function [57]. In the structures of Mtr4, the RecA domains pack against the 
winged helix and ratchet helix domains, forming a central channel for ssRNA. [34, 56]. 
To visualize RNA duplex unwinding in Mtr4, the apo-Mtr4 model was used to 
construct a model of nucleic acid duplex unwinding according to the DNA bound 
structure of the Ski2-like DNA helicase Hel308 (Figure 3-4-B) [34]. The duplex 
























Figure 3-4. Crystal structure of Mtr4 (PDB id: 3L9O) (A) Domain organization of 
Mtr4. Domain names are shown. The winged helix domain is abbreviated as W. (B) 
Cartoon ribbon diagram of Mtr4 (residues 74-1073) from S. cerevisiae. Domains are 
colored as in panel A. To visualize binding of double-stranded nucleic acid, the apo-
form structure was modeled with partially unwound nucleic acid from the Hel308 
structure (Jackson et al., 2010).  The -hairpin loop (colored green) extends from 
RecA2 and facilitates strand separation.  
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facilitates strand separation as the RNA enters into the central channel. As the nucleic 
acid passes through the channel it contacts each of the RecA domains and the ratchet 
helix domains before it exits the helicase at the base. Furthermore, the surface of the 
RNA exit site appears to be structured to accommodate the dimensions of the EXO9 core, 
and thus it has been proposed that Mtr4 feeds RNA directly into the exosome [34].  
 
 
In TRAMP, Mtr4 modulates Poly(A) tail length  
 
As previously mentioned, TRAMP primarily adds only five adenosines to the 
3’end of its RNA targets in vivo [8]. Several studies have identified that this poly(A) tail 
length restriction is due to a secondary functional activity of Mtr4. Mtr4 was first 
implicated in regulating Poly(A) tail length in studies by the Tollervey lab, which showed  
Mtr4 depletion in vivo results in hyperadenylation of TRAMP substrates [52]. More 
recently, in vitro studies by the Jankowsky lab revealed that in the context of TRAMP, 
Mtr4 stimulates polyadenylation by Trf4 until approximately four adenosines are added 
to the RNA [58]. After the critical number of four adenosines is added, polyadenylation is 
markedly suppressed, and when Mtr4 is removed, poly(A) restriction is abolished, 
suggesting that Mtr4 modulates poly(A) tail length. Mutations that prevent helicase 
unwinding activity further indicated that modulation of polymerase activity was not due 
to the unwinding activity of Mtr4. Other studies by the Jankowsky lab have showed that 
isolated Mtr4 and TRAMP both have a distinct preference for unwinding RNA substrates 
with a 4-6 nt poly(A) tail [59]. Together, these results indicate that Mtr4 possesses an 
inherent poly(A) sensing mechanism independent of helicase function, which allows the 
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helicase to identify the number of 3’adenosines and stimulate Poly(A) addition until the 
preferred number of terminal adenosines is acquired.  
Modulating the activity of another protein by identifying particular nucleic acid 
features is unprecedented amongst RNA helicases. Central to this unique function is 
Mtr4s ability to identify and discriminate between substrates that have a poly(A) tail and 
those that do not. A recent publication by our group [60] revealed that Mtr4 uses specific 
sequences located on the ratchet helix of domain 4 to identify RNA poly(A) tails. 
Specifically, R1030 (conserved in Mtr4 homologues) is used to detect 3’ poly(A) 
sequences and promote unwinding of polyadenylated RNA substrates in vitro. Mutation 
of R1030 resulted in decreased unwinding rates of polyadenylated RNA to levels 
comparable to substrates without a poly(A) tail.  These findings correlate with the RNA-
bound crystal structure which showed direct interactions between R1030 and a RNA 
adenine base.   
 
Mtr4 helicase activity is stimulated by TRAMP 
Another interesting feature of Mtr4 function is that its RNA unwinding rate is 
enhanced by nine-fold in the context of TRAMP [59]. Because Mtr4 has some functions 
independent of TRAMP, this regulation of Mtr4 activity could be used to help avoid the 
energy cost of unwinding substrates that have not first been identified by TRAMP. 
Intriguingly, the increase in unwinding activity upon TRAMP formation is observed 
regardless of poly(A) tail length, suggesting that formation of TRAMP independently 
facilities modulation of  both Trf4 polyadenylation and Mtr4 helicase activity.  However, 
it is not clear how Mtr4s interaction with Air2-Trf4 stimulates helicase unwinding rates. 
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One possibility is that binding of Air2-Trf4 causes a structural rearrangement of Mtr4 
that improves RNA substrate binding, ATP binding, or ATPase activity. Such protein-
induced conformational changes have been demonstrated to enhance helicase activity for 
a variety of DExH-box helicases [61-64]. Comparatively, in vitro studies show that 
TRAMP has an elevated ATP binding affinity compared to Mtr4 alone, and importantly, 
this increased affinity for ATP is not due to the adenylation activity of Trf4 (which also 
requires ATP). This observation raises the possibility that binding of Mtr4 to Air2-Trf4 
increases Mtr4s ATP binding affinity, which could facilitate the enhanced helicase 
activity observed in TRAMP. A better understanding of  helicase activity modulation in 
TRAMP requires additional knowledge of how the Air2-Trf4 heterodimer interacts with 
Mtr4. Accordingly, in Chapter 5 of this dissertation, I a direct binding interaction is 
identified between Air2 and the ATP binding domains of Mtr4 (RecA domains).    
 
Concluding remarks 
The central goal of research presented in the following chapters of this 
dissertation is to extend the functional and mechanistic characterization of Air1 and Air2 
in the context of their various binding interactions and physiological implications therein. 
Air1 and Air2 are functionally multi-faceted proteins capable of associating with various 
protein-partners and RNA species to regulate the cellular levels many RNA types.  In 
Chapter 5, a previously unknown binding interface is identified between Air2 and the 
TRAMP complex component Mtr4. That work successfully narrows down an Air2-Mtr4 
binding interface that includes the first 29 amino acids of Air2 and the RecA domains of 
Mtr4. This interaction likely explains a key functionality of helicase regulation in 
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TRAMP. Chapter 6 describes preliminary studies and directions for future efforts aimed 
at characterizing the binding interactions of Air proteins to Mtr4, and the 
methyltransferase protein Hmt1. Collectively, these efforts provide important 
characterization of Air1 and Air2 protein binding interactions with different protein 
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A COMPREHENSIVE DESCRIPTION OF METHODS USED TO CHARACTERIZE 
AIR PROTEINS  
 
ABSTRACT 
Many methodologies have been developed in order to conduct structural and 
biochemical studies of Air-proteins and other TRAMP components. These methods 
include construction of expression constructs, purification strategies, protein binding 
studies, and crystallization. Methods were also developed for conducting binding studies 
and initiating crystallization trials. This chapter describes detailed methods used to 
characterize TRAMP proteins, with a particular emphasis on Air1 and Air2.  The 
expression constructs and purification strategies mentioned are those that have produced 
the greatest amount of protein expression and purification yields. 
 
   
INTRODUCTION 
 
All three protein subunits of TRAMP including both of the Air proteins (Air1 and 
Air2), Trf4, and Mtr4 has been studied as part of this dissertation work.  Many obstacles 
were overcome to develop methods for protein expression and purification of isolated 
proteins and protein co-complexes. Assays for characterizing protein binding interactions 
were also developed, and several crystallization studies for TRAMP proteins have been 
initiated.  
One of the major obstacles encountered during this research was the difficulty of 
expression and purification of recombinant TRAMP proteins. At the beginning of this 
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dissertation work the only protein subunit of TRAMP that had been successfully 
expressed in E.coli was Mtr4. My efforts started with developing a protocol to express 
and purify isolated Trf4. Initial protein expression trials were conducted using various 
expression and growth parameters in both E.coli and yeast. To overcome difficulties in 
expression and solubility, a protein refolding protocol was developed that could 
successfully isolate a soluble form of truncated Trf4.  
A soluble full-length form of Trf4 was later obtained by co-expressing Trf4 with 
another TRAMP component, the zinc knuckle protein Air2. Both proteins were co-
expressed on a single plasmid (pET-Duet1) which resulted in soluble Trf4-Air2 
complexes that could be purified. In addition to full length proteins, different truncation 
mutants of Trf4 and Air2 were also cloned into the same co-expression plasmid. These 
constructs also produced soluble Trf4-Air2 complexes that were purified and used for 
many crystallization screening trials. Unfortunately, none of those trials have produced 
protein crystals. However, those expression constructs and purifications methods will 
likely be of value for future functional and structural studies.    
The greatest amount of success in expression and purification of TRAMP 
complex proteins has been with the zinc knuckle proteins Air1 and Air2. In that work 
many different truncation mutants and protocols were developed to successfully purify 
both of the Air-proteins. Purified Air1 and Air2 have been used to characterize important 
binding interactions between Air-proteins and the helicase Mtr4 (Chapter 5), as well as 
binding interactions between Air-proteins and proteins that are not part of the TRAMP 
complex, such as the methyltransferase Hmt1 (Chapter 6). In addition, many 
crystallization trials have been initiated using Air protein truncation mutants. These 
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crystallization trials include co-crystallization of Air-proteins with Mtr4 and with Hmt1. 
In both of those cases, crystals have been obtained and are awaiting x-ray diffraction 
analysis. 
This chapter describes in detail various methods that have been developed and 
used during my dissertation research on proteins from the TRAMP complex. It is 
anticipated that this chapter will serve as a useful guide for future researchers studying 
proteins within the TRAMP complex. Particular attention is paid to methods used for 
expression and purification of the Air proteins.   
 
 EXPRESSION AND PURIFICATION OF RECOMBINANT PROTEINS 
 
 
Expression and purification of Trf4 
Expression analysis of isolated Trf4 was initiated by inserting the full-length Trf4 
gene sequence from S.cerevisiae into a pET 151-D-topo E. coli expression vector 
(Invitrogen). Primer design and insertion of Trf4 was performed following the pET 151-
D-topo manual. All expression tests using this full length Trf4 construct resulted in no 
detectable expression. To improve expression of Trf4, PCR primers were designed to 
amplify a truncation mutant of Trf4 encoding residues 113-516 (Trf4113-516). These 
residues encompass the region of Trf4 exhibited in the Trf4-Air2 crystal structure (Trf4 
residues 159-481) which includes the Trf4 catalytic and central domains [1]. Trf4113-516 
also contains residues specified as a minimal interaction region with Mtr4 by yeast two 
hybrid analysis [2, 3]. The PCR primers used for amplification were ordered from a 
commercial vendor (Integrated DNA Technologies), and the full-length Trf4 construct 
was used as a template for the PCR reaction. The purified PCR product was then inserted 
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into an empty pET 151-D-topo vector using restriction cloning. The resulting construct 
was expressed in BL21(DE3) codon+RIL  E.coli cells (Agilent Technologies) using 
IPTG induction and auto-induction protocols [4, 5]. Cell lysis was performed by re-
suspending cells in lysis buffer (10% glycerol, 500mM NaCl, 2mM β-ME, 10mM 
imidazole) followed by sonication, and centrifugation. SDS-PAGE analysis indicated that 
the truncated form of Trf4 was highly expressed, but the protein was only observed in the 
insoluble fraction.  
 
Denaturation and refolding of Trf4113-516 
A protein denaturing-refolding protocol has been used to acquire soluble Trf4113-
516. Approximately 20g of cells were re-suspended in lysis buffer, lysed by sonication, 
and centrifuged. The insoluble fraction (cell-pellet from centrifugation) was then re-
suspended in lysis buffer containing 6M urea. The 6M Urea solution was centrifuged at 
20,000 rpm and the soluble fraction was dialyzed step-wise to 250mM urea. The 
following day, protein was refolded on a Ni-affinity column by adding the 250mM urea 
solution to nickel resin followed by washing and eluting with solutions containing no 
urea. Refolded Trf4113-516 was then further purified using heparin-affinity 
chromatography. SDS-PAGE analysis revealed that this purification strategy yielded 
recombinant Trf4113-516 protein that was greater than 80% pure. This refolding procedure 
yielded approximately 3mg of Trf4113-516 from a 2 L growth.  To date, this is the only 






Co-expression and co-purification of Trf4-Air2 
 
 
Expression construct design 
 For expression and purification of a Trf4-Air2 heterodimer, a pET-Duet1 
expression plasmid containing the full length genes of Trf4 and Air2 was obtained from a 
collaborator (Dr. Echard Jankowsky at Case Western Reserve University). This construct 
contains a full-length Air2 gene with an N‐terminal 6x‐histidine tag in cloning site 1, and 
the full-length Trf4 gene in cloning site 2. Using that construct as a template, a second 
pETduet1 Trf4-Air2 expression construct was made. This construct is analogous to the 
former except the Air2 gene has been truncated to express only amino acids 1-223.  The 
truncated Air2 gene was created by site directed mutagenesis following a modified 
version of the QuickChangeTM Site-Directed Mutagenesis protocol (Agilent 
Technologies). The only modification to the QuickChangeTM protocol was that the 
recommended polymerase and buffer was substituted with PfuUltraTM polymerase and 
PfuUltra Buffer (Stratagene). The Air2 mutagenesis replaced the codon encoding Air2 
Ser224 with STOP224. The mutagenesis site was identified using sequence analysis and 
secondary structural prediction to identify a suitable site approximately downstream of 
the Air2 zinc knuckle 5 motif.  The Air2 protein encoded by this construct contains the 
N-terminus and all five Zinc knuckles. 
 
Expression and purification 
Co-expression of Trf4 with Air2 alleviates some of the intractable problems (such 
as no expression, low solubility, and protein aggregation) that I have encountered upon 
expression and purification of isolated proteins. For example, no expression is detectable 
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in other constructs that contain isolated full-length versions of Air1, Air2, or Trf4. In 
addition, all other constructs that contain isolated truncation mutants express proteins that 
generally have low solubility and aggregate during gel filtration. In contrast, each of the 
Trf4-Air2 pETduet1 constructs mentioned above express Trf4-Air2 heterodimers that are 
nearly completely soluble and do not form aggregates during gel filtration.   
An identical procedure has been used to express and purify each of the Trf4-Air2 
heterodimers. Protein expression was induced in BL21(DE3) codon+RIL  E.coli cells 
(Agilent Technologies) using an auto induction protocol [5]. Cells were grown in 2.5 L 
baffled Erlenmeyer flasks with a culture volume of 500 mL autoinduction media.  
Appropriate antibiotics were added to the growth media for selectable resistance 
(ampicillin and chloramphenicol). Because the zinc knuckles motifs of Air2 require zinc 
ions to fold properly, ZnSO4 (250uM) was also added to growth media prior to 
inoculation with E.coli cells. Cell cultures were incubated at 37◦ C with shaking at 300 
rpm for five hours. After the initial incubation, cultures were moved to a room 
temperature shaker (220 rpm) for an additional 24 hours. Cells were harvested by 
centrifugation and stored at -80◦ C.   
 
Table 4-1. Buffer solutions for Air protein preparations 
Buffer component   Lysis Buffer Buffer A Buffer B Sizing 
Buffer 
Glycerol 10.00% 10.00% 10.00% 10.00% 
HEPES pH 7.5 50 mM 50 mM 50 mM 50 mM 
-ME 2 mM 2 mM 2 mM 2 mM 
NaCl 500 mM 150 mM 1 M 100 mM 




Cell lysis was performed by first re-suspending cell pellets in Lysis Buffer (Table 
4-1) containing 10mM imidazole and protease inhibitors (1 µg/mL aprotinin, 1.4 µg/mL 
pepstatin, and 1 µg/mL leupeptin) and lysozyme (0.2mg/mL). Approximately 3 mL Lysis 
Buffer was added for every 1 mg of cells. Cells were lysed by sonication followed by 
centrifugation at 20,000 rpm for 30 minutes at 4◦ C. The clarified lysate was then added 
to 5 mL of Qiagen or GE brand nickel-affinity resin for 1 hour at 4◦ C. After incubation 
the Ni resin was washed with 500 mL lysis buffer, followed by 200 mL Buffer B, and 
then 100 mL Buffer A (Table 4-1) protein was eluted with 50 mL Buffer A containing 
500 mM imidazole. Ni-column elutions were loaded directly onto a 5 mL heparin column 
pre-equilibrated with Buffer A. The majority of contaminating proteins remaining after 
the Ni-column step flowed through the heparin column. A 100 mL gradient from 0 to 
100% Buffer B was performed using AKTA prime chromatography system. Protein 
eluted from the heparin column at approximately 40% Buffer B (500mM NaCl). SDS-
PAGE analysis showed that the Trf4-Air2 complex was purified to greater than 80% 
purity. However, two major contaminating bands (the majority of contaminants) were 
observed that run approximately 5 and 10 kDa below the Air2 band. These bands were 
later identified as Air2 degradation products (verified by western blot analysis). Notably, 
these two degradation bands are observed in every preparation of Air1 and Air2. 
The majority of Air2 degradation can be removed using a Phenyl HP hydrophobic 
interaction column. Therefore, heparin elutions were dialyzed against HIC Buffer A 
(Buffer A in which the salt component is 1 M AmSO4) and loaded onto a phenyl column. 
The majority of all Air2 degradation products flow through the phenyl column. A 100 
mL gradient of 0-100% HIC Buffer B (Buffer B in which the salt component is 100mM 
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AmSO4) was then performed. After Phenyl purification the elutions were added to a 
Superdex 200 26/60 gel-filtration column pre-equilibrated with Buffer A without ZnSO4. 
Each of the Trf4-Air2 heterodimers elute from the gel filtration column as a single peak 
according to its molecular weight. The final purified proteins are more than 97% pure and 
can be concentrated (in a spin concentrator) to at least 15mg/mL. Polyadenylation 
activity of purified recombinant proteins produced by this protocol has been verified by 
our collaborators in the Jankowsky lab. Furthermore, I have performed this preparation 
many times and tested over 2000 crystallization conditions. No crystals were obtained 
from these trials. The crystal structure of Air2-Trf4 reported by Hamill et al. [1] suggests 
that further truncations of Trf4 and Air2 may be required to obtain crystals.  
 Although Trf4-Air2 heterodimers can be successfully purified, two major 
problems exist with the aforementioned protocol. The first major concern is that although 
these co-expression constructs enable protein expression, the amount of expression is still 
not optimal. Second, the purification procedure requires several steps over multiple days. 
Together, these issues prohibit large scale production of purified proteins. The most 
efficient protein preps that I conducted with these constructs and protocol yielded 
approximately 1 mg of purified Trf4-Air2 from 1L culture.  
 
Expression and purification of codon optimized Air1 and Air2 
 
Construct design 
To improve expression and purification yield of isolated Air1 and Air2 proteins, 
codon optimized genes (optimized for E,coli expression) of Air1 and Air2 were 
purchased from a commercial vendor (Genscript). Both of the codon optimized genes that 
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were purchased contain coding sequences for the first amino acid through zinc knuckle 
five (N-ZnK5). Specifically, the codon optimized gene sequences were each designed to 
terminate according to the last residue of Air2 that is observed in the Air2 (ZnK4-5)-Trf4 
crystal structure. In that crystal structure the last Air2 residue is aa198, which resides 31 
residues down-stream of ZnK5. In the Air1 sequence, the homologous amino acid is 
aa209. Accordingly, the codon optimized genes contain the sequences coding for amino 
acids 1-209 of Air1 (Air1 N-ZnK5) and amino acids 1-198 of Air2 (Air2 N-ZnK5). In 
addition to coding sequences, the codon optimized genes were designed to also contain 
sequences at the N-terminus (preceding the coding sequence) for a TEV cleavable 6x-
histidine tag and a FLAG-tag. The N-terminus of each codon optimized gene is shown in 
(Figure 4-1B). The 6x-histidine tag was added to aid purification and the FLAG-tag was 
added to facilitate pull-down studies using anti-FLAG resin. Each codon optimized gene 
arrived from the vendor in a shuttle vector. Therefore, appropriate restriction enzyme 
sites were designed to flank the N- and C-termini in order to cut and paste the sequences 
directly into the expression vector pET-Duet1 (cloning site1). In addition, a BamHI site 
was also designed into the sequence downstream of the FLAG-tag so that genes without 
any tags could also be inserted directly into pET-Duet1 (cloning site1). As a caution to 
future researchers, it should be noted that although the FLAG-tagged Air2 sequence can 
be inserted directly into pET-Duet1, the BamHI sight is out of frame. This was due to a 
mistake in the original sequence design. However, an in-frame Air2 (N-ZnK5) gene 
sequence was PCR amplified using the codon optimized gene as a template and cloned 
into empty pET-Duet1. To date, Both FLAG-tagged and non-FLAG tagged versions of 








To characterize regions of Air1 that are important for function (such as protein-
protein interactions), a variety of truncation mutants have been produced by PCR using 
the codon optimized Air1 gene as a template, followed by restriction cloning into pET 
duet1 (Figure 4-1A). Design of these truncation mutants focused on different ZnKs of 
Air1 and the N-terminus. Each of the codon optimized Air1 genes shown in Figure 4-1 
can be purified to > 90% purity. 
 
General cautions about Air-protein preparation 
 Before I describe expression and purification of Air1 proteins, some words of 
general caution should be given about working with the Air1 or Air2. First, although 
protein expression is greatly improved by codon optimized genes, about 50-70% of 
expressed protein is insoluble. This solubility issue has been observed upon expression of 
all Air1 and Air2 constructs tested. Because of this problem, large growths of 4-6 liters 
are typically grown for each preparation. Second, degradation products are commonly 
Figure 4-1. Air1 and Air2 codon optimized expression constructs. (A) Overview of Air1 
and Air2 codon optimized gene sequence. Each construct shown has been made with and 
without a FLAG-tag. (B) The N-terminus of codon optimized gene sequences.  
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observed that run 5-10 kDa below Air-proteins in SDS-PAGE analysis. I have found that 
the best way to avoid these degradation products is to avoid growing cells beyond the 
recommended time (indicated below) and maintain protein solutions at 4◦ C throughout 
the entire preparation. For example, during lysis I incubate cells in an ice slurry and avoid 
sonicating more than 15 second intervals at a time. I also perform Ni-column batch 
binding and elutions in the 4◦ C room.  The final caution is that Air proteins are generally 
prone to aggregation and precipitation. To help avoid this problem, at least 12% glycerol 
should be used in all buffers; 12% glycerol is especially required during protein 
concentration procedures. Protein precipitation also seems to occur while concentrating if 
imidazole is present in the buffer solution.  Air-proteins will also precipitate if there is a 
sudden change in buffer solutions. For example, I have observed precipitation when 
buffer exchanging by directly adding a volume of exchange buffer that is more than 25% 
of the total protein solution volume. Buffer exchanging by dialysis also causes protein 
precipitation. To avoid protein precipitation during buffer exchanges, researchers should 
use gel filtration, affinity chromatography, or directly add a volume of exchange buffer 
that is no more than 20 % of the total protein solution volume. Finally, protein 
preparations that are prolonged to more than 72 hours typically result in protein 
aggregation and precipitate. Therefore, Air proteins should be purified in less than three 
days.    
 
Expression and purification of Air1 proteins 
 
 The following general method was used to express and purify different Air1 
proteins expressed by codon optimized pET-Duet1 constructs. Expression constructs 
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were transformed into in BL21 (DE3) codon+RIL E.coli cells (Agilent Technologies).  
Single colonies from a fresh transformation plate or  a glycerol stock was used to 
inoculate an overnight starter culture consisting of 30 mL LB media (in a 75 mL baffled 
flask) to which ZnSO4 was added to a final concentration of 250 µM. Appropriate 
antibiotics were also added to all culture media (ampicillin and chloramphenicol). Starter 
cultures were grown at 37◦ C for 12-16 hours (overnight). Approximately 5 mL of the 
starter culture was then used to inoculate 500 mL of media (also containing 250 uM 
ZnSO4) in 2.5 L baffled flasks. The overnight culture can be used to inoculate either LB 
or super-broth media (a nutrient rich media). Equal protein is produced by either growth 
media, the difference between the two is cost and time. LB growths are less expensive 
and require 18 hours of growth after induction, whereas super-broth growths must be 
harvested 4 hours after induction. Growth beyond these time-points results in a higher 
proportion of insoluble protein and protein degradation. After the overnight culture was 
added, the larger cell cultures were incubated at 37◦ C with shaking at 300 rpm until 
culture density reached an OD600 of 0.6-0.8 (1.5-2.5 hours). Protein expression was then 
induced by adding 0.3 mM IPTG. Cultures were then moved to a room temperature 
shaker (180-200 rpm) for 4-16 hours depending on the growth media (as indicated 
above). Cells were harvested by centrifugation and stored at -80◦ C. 
 During protein purification, initial buffers including lysis buffer and buffers used 
during Ni-column procedures all contained 200 µM ZnSO4. This was done to help ensure 
that Air2 zinc knuckles did not exchange zinc ions for nickel ions during the Ni-column 
purification step. To begin protein purification, frozen cells were re-suspended in lysis 
buffer (Table 1-1) containing 10 mM imidazole and protease inhibitors (1 µg/mL 
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aprotinin, 1.4 µg/mL pepstatin, and 1 µg/mL leupeptin) and lysozyme (0.2mg/mL). 
Approximately 3 mL lysis buffer was added for every 1 mg of cells. Cells were lysed by 
sonication followed by centrifugation at 20,000 rpm for 30 minutes at 4◦ C. The clarified 
lysate was then added to 5 mL of GOLDBIO or GE brand nickel-affinity resin for 1 hour 
at 4◦ C. After incubation the Ni-resin was washed with 700 mL lysis buffer, followed by 
200 mL buffer B, and then 100 mL buffer A (Table 1-2). These thorough washing steps 
are necessary to obtain the best purity results. Throughout all of my preparations of 
different Air proteins, The Ni-column step was the most important step for purification, 
and extensive washing during this step made a big difference in the final quantity of 
purified protein obtained. Protein was eluted from the Ni-column in three elution steps. 
Each elution contained 20 mL of buffer A containing 500 mM imidazole which was 
incubated on the nickel resin for five minutes prior to elution.  
The Ni-column elutions were then loaded directly onto a 5 mL heparin column 
pre-equilibrated with buffer A (containing no ZnSO4). A 100 mL gradient from 0 to 
100% buffer B was performed using AKTA prime or AKTA purifier chromatography 
system. The Air1 proteins typically elute from a heparin column as a very broad peak that 
spans about 80 mL from 30% -70% buffer B (400-800 mM NaCl). Purified protein that is 
80%-90% pure is typically found in only 10-20 mL of elutions within this broad peak. 
This is a point where much protein can be lost (especially if the purification during the 
Ni-column step was not efficient). A typical preparation of protein from a 6 L growth 
results in 10-15 mg of purified protein after heparin. If 80-90% purity is suitable then 
protein can be buffer exchanged at this point and frozen. If increased purification is 
needed then gel filtration can be used. 
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For purification by gel filtration, Air1 protein solutions were first concentrated 
using a standard spin-concentrator. Protein concentration was carried out by 
centrifugation in the spin-concentrator at 2200 rpm for 15 minute intervals. Protein was 
mixed sufficiently between each spin using a 1mL pipette. The protein solution was 
concentrated to between 1 and 5 mL and then loaded into an injection loop of the AKTA 
prime/purifier system to which a Superdex 200 26/60 column was attached. The gel 
filtration column was pre-equilibrated with sizing buffer (Table 4-2) and ran overnight. 
All of the Air1 proteins (and Air2 proteins) elute off of the sizing column in multiple 
peaks. One peak is an Air-protein aggregate that elutes in the void volume. The other 
peaks also primarily contain the Air-protein and different levels of minor contaminants. 
The contaminants are generally proteins that are 70-80 kDa is size as well as Air protein 
degradation products. There is always a peak containing purified protein that elutes off 
the column at a volume that is consistent with an Air protein monomer. However, the size 
of this peak, and the relative amount of protein that it represents has been inconsistent 
between multiple preps of the same protein. The reason for this inconsistency is not 
known. The best method for increasing the amount of purified Air protein monomer on 
gel filtration is to use a buffer that contains at or below 100 mM NaCl. In all Air-protein 
preps tested, a NaCl concentration of around 50 mM NaCl drastically reduced the 
aggregate peak and increased the amount of protein obtained from the peak 
corresponding to a protein monomer. The most efficient preparations Air1 (N-ZnK5) and 
Air2 (N-ZnK5) from a 6 L growth after gel filtration produced only 1-2 mg of protein. 
This small amount is due mainly to the fact that the majority of Air protein either elutes 
as an aggregate or elutes with other contaminants. Again, the majority of contaminants 
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are often Air protein degradation products, and fractions that contained these 
contaminants were not pooled.   
 
Modified purification of Air2 proteins and Air1 ZnK4-5 
In addition to the above protocol, the Air2 proteins and only Air1 ZnKs 4-5 can 
be purified in a much more effective way. The only difference to the Air1 purification 
protocol is that a mono-Q column is used in place of a heparin column. Two Air2 protein 
constructs, Air2 N-ZnK5 and N-ZnK3, and Air1 ZnKs4-5 have been purified by this 
method. In each case the Air-proteins flow through the mono-Q column and all observed 
contaminants stick to the column. The result is protein that is purified to greater than 98% 
purity (indicated by SDS-PAGE). In addition, The Air1 ZnK4-5 that was purified using a 
Q-column eluted off of a gel filtration column as a single peak without aggregation. 
Furthermore 10 mg of pure protein was obtained from that prep. This is interesting 
because other preps of Air1 ZnK4-5 that involved a heparin column produced a large 
aggregate peak during gel filtration. The reason for this difference is not known, but the 
Q-column method seems to work. Noteworthy, other Air1 proteins stick to the Q-column 
without further purification. Air2 constructs have not been analyzed by gel filtration 
following mono-Q purification. This should be done by future researchers.     
 
Co-expression and purification of Air2 (N-ZnK5) and Hmt1 (K13S) 
 For functional studies regarding Air proteins and Hmt1, undergraduate 
researchers (Emily Frampton and Kaleb Chatland) and I have begun constructing co-
expression constructs of Air-proteins and Hmt1. Currently, we have been successful in 
producing one of these construct which contains codon optimized Air2 (N-ZnK5) in 
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cloning site 1 and Hmt1 (K13S) in cloning site 2. We have also been successful in co-
purifying these proteins and growing crystals of proteins purified using that protocol.  
 
Expression and purification  
Like other described protein expression methods, the Air2-Hmt1 construct was 
transformed into BL21 (DE3) codon+RIL E.coli cells. A single colony from a fresh 
transformation plate was used to inoculate a 30 mL LB overnight culture supplemented 
with 250 µM ZnSO4 and antibiotics (ampicillin and chloramphenicol). The overnight   
starter cultures were grown at 37◦ C for 16 hours (overnight). Approximately 5 mL of the 
starter culture was then used to inoculate four 500 mL cultures of LB media (also 
containing 250 µM ZnSO4) in 2.5 L baffled flasks. The larger cell cultures were then 
incubated at 37◦ C with shaking at 300 rpm until culture density reached an OD600 of 
0.3. Protein expression was then induced by adding 0.05 mM IPTG. Cultures were then 
moved to a room temperature shaker that was adjusted to shake flasks at 200 rpm for 20 
hours. After 20 hours, cells were harvested and stored at -80◦ C. 
Cells were lysed as described above for Air1 protein preparations. The one 
difference is that the lysis buffer used contained tris buffer pH 7.5, 50 mM NaCl, and no 
imidazole. Low salt was used in order to ensure complex formation. Other studies have 
shown that when imidazole is added, Hmt1 does not co-elute with Air2 during Ni-column 
purification. Instead, when imidazole is added a higher proportion of equal molar 
amounts of Air2 and Hmt1 are observed in the flow-through, suggesting that Air2-Hmt1 
complexes may have a weaker affinity for Ni-resin compared to isolated Air2. Another 
interesting feature that should be pointed out is that unlike isolated Air2 preparations, co-
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expression with Hmt1 results in greater than 80% soluble Air2 protein and no Air2 
degradation products are observed by SDS-PAGE.  After nickel column purification the 
proteins are greater than 90% pure.  
 Nickel column elutions were pooled and concentrated to 5 mL using a spin-
concentrator. The concentrator was centrifuged at 2000 rpm at 15 minute intervals and 
protein was mixed sufficiently between each spin using a 1mL pipette. After 
concentrating to 5 mL the protein solution was loaded into an injection loop of the AKTA 
purifier system and loaded onto a Superdex 200 26/60 column. The gel filtration column 
was pre-equilibrated with sizing buffer similar to that indicated in Table 4-1. The key 
differences again are tris pH 7.5 and 50mM NaCl) and run overnight. The elution profile 
of gel filtration showed 6 total peaks and an aggregation peak in the void volume. 
According to the chromatogram, the first two peaks (indicated as peak 1 and peak 2 in lab 
notebooks) were about three times larger than the other peaks. SDS-PAGE analysis 
revealed that peak 2 contained the highest amount of purified Air2 and Hmt1 that 
additionally appeared to be in equal molar ratio amounts. Peak 2 eluted from the gel 
filtration column at 170 mL which corresponds to a protein complex of about 160-200 
kilodaltons. Fractions corresponding to peak 2 were pooled and concentrated to 20 
mg/mL according to the extinction coefficient for Hmt1-Air2 (N-ZnK5) which was 
predicted by the ExPASy-ProtParam online bioinformatics tool [6]. 
 
Improved expression and purification of isolated Air2 (N-ZnK5) 
 
 Effective purification of isolated Air2 can be achieved by co-expressing Air2 with 
Hmt1. As mentioned in the previous section, co-expression of Air2 (N-ZnK5) with Hmt1 
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produces Air2 that is greater than 80% soluble and does not appear to have the 
degradation products observed when Air2 is expressed alone.  After co-expression with 
Hmt1, stable Air2 can be isolated using buffers containing high concentrations of salt 
during lysis and initial purification steps. Below, is a general description of a method 
used to purify stable Air2 (N-ZnK5) after co-expression with Hmt1.  
 
Air2 (N-ZnK5) Purification  
 
 For the following protein preparation the E.coli growth parameters and protein 
expression was identical to that described above for Air2-Hmt1 co-expression. To begin 
the lysis procedure, approximately 20 grams of cells (corresponding to 2 liters of  LB  
culture) were re-suspended in 60 mL Lysis Buffer (Table 4-2) containing protease 
inhibitors (1 µg/mL aprotinin, 1.4 µg/mL pepstatin, and 1 µg/mL leupeptin) and  
lysozyme (0.2mg/mL). The solution was incubated on ice 20 minutes, sonicated, and then 
centrifuged at 18,000 rpm for 40 minutes. The soluble lysate was added to 7 mL GE 
brand Nickel-resin (pre-equilibrated with Lysis Buffer) and incubated at 4° C on a 
rotating table for 45 minutes. After incubation, the Ni-resin was added to a 50 mL hand-
column and washed with 700 mL Lysis Buffer (Table 4-2) followed by 100 mL Wash 
Buffer 1 (Table 4-2). Notably, Wash Buffer 1 contains 1M AmSO4, and washes with that 
buffer can be used to help remove any excess Hmt1. The Ni-resin was finally washed 
with 100 mL Buffer A. Bound protein was then isolated from the Ni-resin by incubating 
the resin for 5 minutes with 15 mL Buffer A containing 300 mM imidazole followed by 
elution. The final elution step was repeated three times. Different preps have shown (by  
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SDS-PAGE) that after Ni-resin purification, Air2 is typically purified to greater than 90% 
purity with minor protein contaminants around 70-75 kDa in size.  
 Further purification of Air2 (N-ZnK5) can be obtained using an anion exchange 
column. The three Ni-column elutions (described above) were pooled (~45 mL total) and 
loaded onto a 5 mL mono-Q column pre-equilibrated with Buffer A (Table 4-2). A 100 
mL gradient from 0 to 100% Buffer B (Table 4-2) was performed using AKTA purifier 
chromatography system. Importantly, Air2 (N-ZnK5) flows through the mono-Q column 
while all remaining contaminants do not, resulting in a flow-through sample that contains 
stable Air2 purified to greater than 98% purity. The purified solution was then buffer 
exchanged to Buffer C (Table 4-2) using a HiPrep 26/10 desalting column (GE 
Healthcare Life Sciences). Buffer exchanging by gel filtration is necessary because 
concentrating with imidazole present results in protein precipitation. After buffer 
exchanging, the protein was concentrated to approximately 8 mg/mL followed by 
addition of 20% glycerol and storage at -80° C.  Air2 has been successfully purified 
Buffer component 
 Lysis Buffer Wash 
Buffer 1 
Buffer A  Buffer B Buffer C 
Glycerol 10.00% 10.00% 12.00% 12.00% 12.00% 
Tris pH 7.5 50 mM 50 mM 50 mM 50 mM 50 mM 
-ME 2 mM 2 mM 2 mM 2 mM 2 mM 
NaCl 1M ---- 150mM 150 mM 100 mM 
AmSO4 ---- 1M ---- ---- ---- 
ZnSO4 0.2M 0.2M 0.2M 0.2M ---- 
Volume used 1 L  200 mL 500 mL 500 mL 500 mL 
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multiple times using the above protocol, and each time approximately 5-10 mg of protein 
was obtained per liter of cell culture.  Moreover, using this protocol provides more than 





Co-crystallization trials of Air2 (N-ZnK5) and Hmt1 (K13S) 
Co-expressed and co-purified Air2 (N-ZnK5) - Hmt1 (K13S) complex (described 
previously) was used for sitting-drop vapor diffusion crystallization screening trials using 
an Art Robbins Gryphon Crystallization Robot (Art Robbins Instruments) located in the 
Johnson lab. Intelli-plate 96-well crystallization plates (Art Robbins Instruments) were 
used for crystallization trials. Five different crystallizations screens each containing 96 
individual crystallization solutions were used to set up five 96-well crystallization plates.  
The crystallizations screens used include the MCSG suite (Microlytic) which consist of 
four different screens (MCSG 1-4), and the INDEX screen (Hampton Research). 
Crystallization plates were incubated at 4◦ C. After three weeks protein crystals were 
observed in many crystallization conditions. Crystals from MCSG 4 at location G4 in the 
96 well plate (well solution is 0.1 M Sodium Citrate:HCl pH 5.6, 10% (w/v) PEG 4000, 
10% (v/v) 2-Propanol) was analyzed for diffraction quality using a home-source x-ray 
generator  (MicroMax-007HF) and detector (Rigaku R-Axis IV++). The cryo-solution 
used for these crystals consisted of the MCSG4-G4 well-solution with 15% glycerol.  All 
three crystals that were analyzed exhibited x-ray diffraction that was consistent with 
protein crystals. The best diffracting crystal diffracted x-rays to 7 Å. Remaining crystals 
in the G4-well were later analyzed by SDS-PAGE and SYPRO Ruby protein gel stain 
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(SIGMA-ALDRICH). The gel analysis confirmed that these crystals contain both Air2 
and Hmt1. Furthermore, another crystal from that same condition was sent to the 
synchrotron source SSRL for diffraction analysis. Unfortunately that particular crystal 
had poor x-ray diffraction (~20Å). However, the diffraction pattern suggested that the 
crystal was indeed protein. Additionally, an x-ray excitation scan was conducted on that 
crystal at SSRL which detected the presence of zinc ions, suggesting that the crystal 
contained Air2 zinc knuckles. Future researchers should consider this particular crystal 
hit for generating Air2-Hmt1 crystals. In addition, other crystallization hits remain 
untested for diffraction quality.    
 
Co-crystallization trials of Air2 (N-29) peptide and Mtr4  
 
Crystallization trials have also been initiated for Air2 N-29 peptide with both full 
length Mtr4 and archless Mtr4. These crystallization trials were initiated by purifying 
Mtr4 proteins according to established protocols. Each of the Mtr4 proteins were 
concentrated to 14-46 mg/mL in crystallization buffer (50mM Hepes pH 7.5, 5% 
glycerol, 100mM NaCl, 2mM β-ME). Approximately 0.1 g of lyophilized unlabeled Air2 
N-29 peptide (synthesized by Dr. Joshua Price at Brigham Young University) was also 
suspended in 100 µl of the same crystallization buffer. The Air2 peptide and Mtr4 
solutions were then mixed with in a molar ratio of 1.2:1.0 Air2:Mtr4. This protein 
solution was incubated for 30 minutes on ice and then crystallization trials were initiated 
using the same equipment and screens described above for Air2-Hmt1 crystallization 
trials. The only difference is that for each Air2-Mtr4 crystallization trial, the five crystal 
screens were set up at both 4◦ C and room temperature. After 3 months, several different 
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crystal hits have been identified only in the trials containing archless Mtr4 at room 
temperature. 
 
Analysis of RNA binding by Air1 and Air2 
 
 To date, only one report has confirmed direct interactions of Air proteins with an 
RNA substrate [7]. In that report NMR and fluorescence anisotropy studies demonstrated 
that Air2 Zinc knuckles 2-4 were involved in binding hypomodified tRNAiMet, and ZnK’s 
1-5 can bind a 15nt poly(A) RNA in vitro. In order to detect and further characterize 
RNA binding by various recombinant Air1/2 proteins, a fluorescence based assay was 
developed which monitors the change in intrinsic fluorescence of Air1/2 proteins as an 
RNA substrate is titrated into an Air1/2 protein solution. This RNA binding assay has 
been used to qualitatively identify binding of purified Air1 (N-ZnK5) and Air2 (N-ZnK5) 
to both U6 snRNA and tRNAimet in vitro. Additional purifications of these and other 
Air1/2-RNA complexes should be used for x-ray crystallography studies.  
 As an example of the assay procedure; purified Air1 (N-ZnK5) was concentrated 
to 2 M in binding buffer (50 mM Hepes pH 7.5, 12% glycerol, 2 mM ME, 50 M 
NaCl) and 1.9 mL was added to a 2 mL quartz cuvette. U6 snRNA and tRNAimet were 
titrated with increasing concentrations (2 -20 M) and the change in fluorescence 
between 320 nm and 400 nm was monitored using a steady-state-photon counting 
spectrofluorometer, PC1 with Vinci software, from ISS Instruments (Antony lab, USU). 
As shown in Figure 4-2, a significant change in fluorescence is observed after the 
addition of a tenfold molar excess of RNA substrate (20 M RNA). Similar results have 











used as a qualitative assessment of Air-RNA interactions to guide potential crystallization 
trials or identify RNA substrates and RNA binding regions of Air proteins. Currently, Air 
protein concentrations below 2 M have not been tested and future researchers are 
encouraged to investigate whether a significant change in intrinsic fluorescence (upon 
RNA binding) can be observed when using nano molar concentrations of Air1/2. If 
changes in fluorescence can be detected while using low enough concentrations of Air 
proteins, then it is likely that a quantitative binding curve could be established to further 
characterize Air-RNA binding interactions.  






Figure 4-2. Air1 (N-ZnK5) binds tRNAiMet in vitro. RNA binding results in a change 
in Air1 intrinsic fluorescence. The change in fluorescence upon addition of 20 M 
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TRAMP ASSEMBLY INVOLVES BINDING INTERACTION OF  





In Saccharomyces cerevisiae many non-coding RNAs are processed and degraded 
by RNA surveillance systems primarily involving the 3’-5’ exonucleolytic activities of 
the nuclear RNA exosome. TRAMP complexes are exosome cofactors that identify and 
polyadenylate RNAs, a process that stimulates their degradation. Each TRAMP complex 
is composed of three proteins, a RNA binding protein (Air1 or Air2), a poly(A) 
polymerase (Trf4 or Trf5) , and a RNA helicase (Mtr4). Previous studies have revealed 
that Air2 and Trf4 form a tight complex, but how an Air2-Trf4 heterodimer associates 
with Mtr4, and how formation of TRAMP modulates Mtr4 helicase activity has been 
poorly characterized. Experiments reported here identify an important interaction site 
between the N-terminus of Air2 and Mtr4. Additionally we show that a homologous 





To avoid the accumulation of aberrant and unneeded RNA transcripts the 
eukaryotic cell has evolved nuclear RNA surveillance pathways which ensure rapid 
turnover of many types of non-coding RNAs. In these pathways a large multimeric 
protein complex called the nuclear RNA exosome serves the primary role for RNA 
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degradation. In Yeast, the nuclear exosome is a ring-like structure composed of nine 
inactive core subunits (exo9-core) that associate with two catalytically active 3’-5’ exo-
ribonucleases Rrp44 (exo10-complex) and Rrp6 (exo11-complex) [1-3]. In vivo, the 
specificity and exonucleolytic activity of the exosome requires additional proteins that 
are collectively referred to as exosome cofactors. TRAMP (Trf4p/Air2p/Mtr4p 
polyadenylation complex)  is a key exosome co-factor that stimulates the degradation of a 
wide variety of RNA substrates including aberrant forms of tRNAs, snoRNAs, rRNA 
processing intermediates, cryptic unstable transcripts (CUTs), and pre-mRNA splicing 
intermediates [4-10]. 
 TRAMP is a three-protein complex composed of a RNA binding zinc-knuckle 
protein (Air1 or Air2), a non-canonical poly(A) polymerase (Trf4 or Trf5), and a RNA 
helicase (Mtr4) [10-12]. In the current model of TRAMP function, Air1/2 identifies 
particular RNA substrates, Trf4/5 adds a short (~4-5 nt) poly(A) tail to the 3’ end of the 
RNA, and Mtr4 unwinds any RNA secondary structure that may exist [10-16]. This 
unwinding and polyadenylation by TRAMP provides an unstructured single stranded 3’ 
end of the RNA, which is a favorable substrate for the exosome to start degrading [14]. In 
this way, TRAMP plays a critical role in ridding the cell of non functional and unwanted 
RNA transcripts. TRAMP mediated RNA surveillance is essential and found throughout 
eukaryotic species from yeast to humans [13, 17]. In humans, defects in RNA 
surveillance and processing have been linked to many disease states [18-20], highlighting 
the importance of understanding the molecular details of RNA surveillance and TRAMP 
complex function. 
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 In the yeast Saccharomyces cerevisiae, each of the Air proteins (Air1 and Air2: 
45% seq. id) and Trf proteins (Trf4 and Trf5: 48% seq. id) are parologues that likely 
arose as result of a whole genome duplication event in S. cerevisiae [21], and therefore 
other eukaryotes have only one ortholog of each. Subsequently, in S. cerevisiae, two 
general types of TRAMP complexes have been described; each one containing Mtr4 and 
different combinations of Air and Trf components. TRAMP4 contains Trf4 and Air2 or 
Air1, whereas TRAMP5 contains Trf5 and only Air1 [10-12, 22]. TRAMP4 and 
TRAMP5 have been shown to have distinct sub-nuclear localizations, and each complex 
is involved in processing specific RNA substrates. For example, Trf5-GFP and Air1-GFP 
fusions are primarily enriched within the nucleolus [23-25], where rRNA transcription 
and processing occurs. Accordingly, TRAMP5 preferentially enhances degradation of 
aberrant rRNA precursors. TRAMP4 is required for polyadenylation and degradation of 
structured RNA such as tRNAimet [12, 23], and regulating levels of transcripts encoding 
proteins involved in carbon metabolism [26]. Despite these differences in RNA 
specificity, growth phenotypes indicate that there is some essential functional overlap 
between the different TRAMP complexes. In S. cerevisiae, none of the Trf or Air 
proteins are individually essential, as single gene deletions do not result in growth defects 
[27, 28]. However, a Trf4Δ Trf5Δ double mutant is inviable [29], and an Air1Δ Air2Δ 
double mutant has a severe growth defect [30]. An Mtr4Δ mutant is also inviable [27]. 
These growth phenotypes further suggest that together the TRAMP complexes (TRAMP4 
and TRAMP5) and their individual subunits perform critical functions, but why assembly 
into a complex is necessary, and how different complexes are assembled is not clear. 
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 Several reports have indicated some functional significance of TRAMP complex 
formation. A crystal structure of Air2-Trf4 and other biochemical studies have made 
clear that Air2 and Trf4 form a tight complex [23, 31], and this Air2-Trf4 heterodimer is 
required for Trf4 polymerase activity in vitro [10-12]. It is still unknown how Mtr4 
interacts with the other TRAMP subunits. However, functional studies have revealed that 
when Mtr4 is bound as part of an in-tact TRAMP complex it serves as a critical regulator 
of the polyadenylation activity of Trf4 on a variety of RNA substrates [16]. Additionally, 
the Air2-Trf4 heterodimer directly stimulates the helicase unwinding activity of Mtr4 
[32]. This 3-way coupling between TRAMP components is presumed to ensure that a 
preferred number of ~4-5 adenosines are added to the 3’end of RNA substrates, which 
enhances duplex unwinding by Mtr4 and provides a docking site for the exosome [16, 
32]. Although these studies highlight important aspects of TRAMP complex assembly, 
how the Air2-Trf4 dimer associates with Mtr4, and how this association might facilitate 
cooperative interactions between protein subunits remains to be described. Understanding 
these important characteristics of TRAMP requires more detail about how the complex is 
assembled. In this work, we identify a direct binding interaction between Air2 and Mtr4. 
In addition, we have narrowed down a binding interface of the two proteins to be located 
within the first 29 amino acids of Air2 and the ATP binding/hydrolysis domains (RecA1 









MATERIALS AND METHODS 
 
 
Recombinant protein expression and purification 
 
 The construction, expression, and purification of full length Mtr4 and Mtr4 
truncation mutants have been described previously [33]. For Air1 residues 1-41, a codon 
optimized gene sequence containing an N-terminal FLAG-tag followed by a 6X His-tag 
was inserted into the co-expression vector pET-Duet1 and transformed into BL21(DE3) 
RIL cells. Cells were grown using superbroth media, and protein expression was induced 
during log-phase of growth with 0.5mM IPTG. Cells were harvested approximately four 





 Binding analysis of Mtr4 to Air2 was carried out using fluorescence anisotropy. 
An Air2 peptide comprising residues 1-29 with an N-terminal fluorescein label was 
obtained from Dr. Joshua Price at Brigham Young University. Binding reactions were 
buffered in 50 mM HEPES (pH 7.5), 100 mM sodium chloride, 0.1 mg/mL BSA, and 
12% glycerol. Concentrations of the labeled Air21-29 peptide was held constant at 80 nM 
and titrated with increasing concentrations of Mtr4. Samples were incubated for three 
minutes after each titration, as changes in anisotropy were not observed beyond this 
incubation time. Anisotropy at each titration point was measured ten times and averaged. 
Anisotropy measurements were obtained using a steady-state-photon counting 
spectrofluorometer, PC1 with Vinci software, from ISS Instruments. Excitation and 
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emission slits were adjusted to 0.5 nm and temperature was maintained at 25°C. The 
excitation wavelength was 495 nm and emission anisotropy was measured at 521 nm. 
 
FLAG-tag pull-down studies 
  
 FLAG-tag co-immunoprecipitation was conducted using batch method in a 2mL 
vessel. Purified recombinant FLAG-tagged Air1(residues 1-41) was incubated with 100l 
of ANTI-FLAG M2 affinity gel (Sigma-Aldrich) and washed with binding buffer (50 
mM HEPES pH 7.5, 100mM NaCl, 5% glycerol). Purified Mtr4 was then added and 
incubated for 1 hour followed by additional washes with binding buffer. Bound proteins 






A 29 amino acid peptide in the N-terminus of Air2 is sufficient for Mtr4 interaction 
 
 The binding interactions that link together the three protein subunits of TRAMP 
have only been described for the binding interface between Air1/2 and Trf4/5 [23, 31, 
34]. However, recent reports by Holub et al. have indicated that the N-terminus of Air2 is 
required for co-immunoprecipitation of an Air2-Trf4 heterodimer with Mtr4 [34], 
suggesting that the N-terminus of Air2 is important for TRAMP assembly.  To test 
whether the N-terminus of Air2 can directly bind Mtr4, we used fluorescence anisotropy 
to analyze binding between Air2 residues 1-29 and purified recombinant Mtr4. As shown 
in Figure 5-1B, a fluorescently labeled Air2 peptide directly bound to full length Mtr4 
























Figure 5-1. A 29 amino acid peptide in the N-terminus of Air2 interacts with the RecA 
domains of Mtr4. (A) Domain analysis of Mtr4 and Air2. Green triangles indicate 
various truncation mutants used for anisotropy analysis. B-E:  Fluorescence anisotropy 
analysis of a Air2 peptide binding to (B) Mtr4 full length, (C) Mtr4 with the 
unstructured N-terminus deleted, (D) Mtr4 with the arch domain deleted, and (E) Mtr4 
consisting of the RecA domains and a C-terminal deletion. 
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peptide to other non-TRAMP proteins (data not shown). To identify the region of Mtr4 
used for binding Air2, we further probed Mtr4-Air2 peptide interactions with truncated 
forms of Mtr4 (Figure 5-1A). Collectively, an N-terminal truncation (Mtr4∆74, Figure 5-
1B), an arch deletion (Mtr4archless; Figure 5-1C), and C-terminal deletion (Mtr41-614, 
Figure 5-1D), all displayed similar binding affinities. Importantly, Mtr41-614 contains a 
small portion of the winged helix domain (residues 576-614) and the RecA1 and RecA2 
domains (domains 1 and 2 in Mtr4) which are involved in ATPase activity and RNA 
binding. From these analyses we conclude that the N-terminus of Air2 directly binds to 
Mtr4. Specifically, this binding interface involves the first 29 residues of Air2 and the 
region of Mtr4 encompassing both of the RecA domains. 
 
The N-terminus of Air1 can facilitate interactions with Mtr4. 
Unlike Air2, Air1 is found in both TRAMP4 (Trf4/Air2(1)/Mtr4) and TRAMP5 
(Trf5/Air1/Mtr4) complexes. Unique protein interactions of Air1 and Air2 within 
TRAMP could be a contributing factor to various substrate specificities or functionality 
of different TRAMP complexes. It is generally assumed that Air1 and Air2 use the same 
conserved residues (IWRxYxL, and zinc knuckle 5) for binding Trf4 and Trf5, 
respectfully [23, 34]. Therefore, we tested if both Air1 and Air2 also use a common 
binding region for interacting with Mtr4. Sequence alignment of the N-termini of Air1 
and Air2 indicate that Air2 residues 1-29 are homologous to the region of Air1 that 
include residues 1-41 (Figure 5-2).  To test if Air1 residues 1-41 can bind Mtr4, we 
conducted pull-down experiments with purified recombinant Air1 residues 1-41 and 
Mtr4. Figure 5-2B reveals that FLAG-tagged Air1 residues 1-41 can effectively pull 
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down Mtr4 in vitro. These results indicate that Air1 and Air2 share a common region at 















 In this work we have revealed that a small peptide in Air2 can directly bind to 
Mtr4, and that a homologous region of Air1 can also form a stable interaction with Mtr4. 
The previous crystal structure of Air2 bound to Trf4 shows that Air2 uses its fifth zinc 
knuckle and a short sequence upstream of that zinc knuckle to bind Trf4. The Air2 
peptide that we have identified as binding to Mtr4 is outside of the Air2-Trf4 binding 
interface, and likely represents a region used to tether the Air2-Trf4 heterodimer to Mtr4. 
Furthermore, our anisotropy measurements indicate that a region encompassing the two 
RecA domains of Mtr4 is used to bind the Air2 peptide, as neither the N-terminal or C-
terminal domains are required for this interaction.  
Figure 5-2. Air1 residues 1-41 bind to Mtr4 in vitro. (A) Sequence alignment of 
Air1 and Air2 N-termini. Identical residues are highlighted orange. Semi-
conserved residues are highlighted light yellow. (B) Pulldown assay with FLAG-
Air1 residues 1-41 and recombinant Mtr4. Bound proteins were eluted with 
FLAG peptide and analyzed by SDS-PAGE 
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Binding of Air2 to the RecA domains of Mtr4 could explain how the helicase 
activity of Mtr4 is modulated in TRAMP. In Mtr4 and other Ski2-like helicases, the 
RecA1 and RecA2 domains contain conserved sequence motifs for binding and 
hydrolysis of ATP, a requirement for helicase function [35]. It has been shown that 
TRAMP formation enhances the unwinding activity of Mtr4 by increasing Mtr4s affinity 
for ATP and increasing rate constants for helicase unwinding [16]. This alteration of 
Mtr4 function by Air2-Trf4 suggests that within the TRAMP complex there is a 
functional coupling between Mtr4 and Air2-Trf4.  It is easy to speculate that this 
coupling is provided via binding of Air2 to the RecA domains, which imparts a 
conformational change in structure that stimulates binding and hydrolysis of ATP. Such 
an arrangement could ensure that unwinding by Mtr4 is directed at RNA substrates that 
have first been identified by Air2-Trf4.  
During the preparation of this manuscript Falk et al. also identified that the N-
terminus of Air2 can bind directly to Mtr4 [36]. Specifically, they showed that a dimeric 
protein complex (connected by a linker) of Trf4 111-490 and Air2 1-190 interacts with 
Mtr4 with high affinity (Kd = 310 nM). A 49 residue deletion of the Trf4 peptide from 
that construct (Trf4 160-490) resulted in lower affinity binding with Kd = 6.9 µM. This 
measurement is very close to our measurements for Kd of the isolated Air2 peptide. Our 
group has also identified a 26 amino acid peptide of Trf5 (residues 98-124) directly binds 
Mtr4 with a modest Kd of 10 µM [37]. The sequence of that Trf5 peptide is conserved in 
Trf4 residues 111-140. Thus, the amino acids corresponding to the isolated Air2 and Trf5 
peptides used by our group reside within the Air2-Trf4 fusion peptide used by Falk et al. 
(Trf4 111-490 and Air2 1-190 ) for their binding studies that showed tight binding to 
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Mtr4 (Kd = 310 nM).  Taken together, these data suggest that a small peptide region of 
Air1/2 (reported in this work) and small peptide region of Trf4/5 function together to 
bind Mtr4 with high affinity.    
The Falk et al. manuscript also presented a crystal structure of the Air2-Trf4 
fusion peptide bound to Mtr4. The model includes Mtr4 residues 117-1073, Trf4 residues 
121-127, and Air2 residues 6-52. The Air2 binding interactions primarily involve Air2 
residues 26, 29, 35, and 44, which form electrostatic interactions with domain 4 of Mtr4 
(Figure 5-3A). Importantly, unlike our solution binding studies; Falk et al did not report 
binding interactions between Air2 residues 1-29 to any portion of the RecA domains. 
Instead, the crystal structure displays a sharp bend at residue 19 which directs the N-
terminus of Air2 away from the bound Mtr4 molecule where it forms multiple binding 
interactions to a symmetry related Mtr4 molecule. This secondary binding interface  
involves Air2 residues 7, 8, 11, and a region of the Mtr4 Arch-domain known as the Fist 
(Mtr4Fist, residues 665-815).  
To verify if binding observed in the crystal structure between Air2 and Mtr4Fist 
represents a bona fide interaction, we performed anisotropy measurements using our 
labeled Air2 peptide to recombinantly purified Mtr4Fist. Figure 5-3-B shows that we 
observed no binding between the Air2 peptide and isolated Mtr4Fist.  Thus, our solution 
binding assays and the crystal structure do not fully agree on the binding interactions 
between Air2 and Mtr4. One explanation for the discrepancy is that in the crystal structure 
the binding of Air2 to a symmetry related Mtr4 molecule is an artifact of crystallization, 
and this crystallization-induced binding precludes native binding of Air2 residues 1-29 to 
the RecA domains. Another possibility is that the interactions observed in the crystal 




















structure may be partially influenced by the Air2-Trf4 construct, which was fused together 
in a non-native conformation to facilitate crystallization. 
 In conclusion, we have identified a region of Air2 that directly binds to Mtr4 and 
likely bridges together the three proteins of TRAMP. As described above, a recent report 
has also identified that the Air2 N-terminus binds to Mtr4. However, our work goes 
Figure 5-3. Binding interactions between the N-terminus of Air2 and Mtr4Fist are not 
observed in vitro. (A) Crystal structure of Mtr4 bound to Trf4 and Air2 peptides. 
Zoomed- in view highlights the binding interface between the Air2 peptide and two 
symmetry related molecules of Mtr4. Air2 peptide and Air2 residues involved in binding 
are colored green. Mtr4 molecules are colored grey. (B) Fluorescence anisotropy analysis 
of labeled Air21-29 peptide binding to recombinant Mtr4Fist. 
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beyond that described by Falk et al, as we have identified a binding interface not 
observed in the crystal structure and not characterized in any other previous study. 
Furthermore, this binding interface may explain modulation of Mtr4 reaction parameters 
observed upon TRAMP complex formation. In addition, we identified that the 
homologous region of Air1 can also bind to Mtr4 in vitro, suggesting that Air2 and Air1 
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SUMMARY AND FUTURE DIRECTIONS 
 
 
Summary: The dehydrogenases R-and S-HPCDH 
 
Throughout biology there are few examples of homologous enzymes that function 
within the same biological pathway to catalyze similar reactions with opposite 
stereospecificity. This unique characteristic of R- and S-HPCDH makes them an ideal 
model system to study enzymatic mechanisms of substrate recognition, specifically 
stereospecificity. When I began this work a substantial amount of functional and 
mechanistic studies had already characterized many stereospecific properties of R- and S-
HPCDH. For example, kinetic studies revealed that stereospecificity is governed by 
alternative kinetic mechanisms in each enzyme [1]. However, the structural differences 
between the enzymes that enable them to have opposing stereospecificity had not been 
determined. Chapter 4 describes the first x-ray crystal structure of S-HPCDH, and the 
first substrate-bound crystal structure of either enzyme. Using the S-HPCDH crystal 
structure and a previously determined crystal structure of R-SHPCDH, I presented a 
structural comparison of R-and S-HPCDH that revealed previously unknown sequence 
and structural differences employed by each enzyme to facilitate stereospecificity.  
The main structural difference between R- and S-HPCDH is that each enzyme has 
a unique substrate binding pocket. When compared to each other, the substrate binding 
pockets share a common catalytic site, but differ in orientation as they lead away from the 
catalytic site to alternative substrate binding residues at the periphery of each pocket. In 
addition, the substrate-bound form of S-HPCDH provided the ability to analyze substrate 
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binding in these enzymes for the first time. These observations combined with previously 
reported kinetic data now provide a thorough model of stereospecificity for R- and S-
HPCDH.  In S-HPCDH, the difference in substrate binding pocket orientation provides a 
binding pocket that accommodates the S-substrate isoform but sterically hinders binding 
of the R-substrate isoform. Specifically, when the R-substrate (R-HPC) is modeled into 
the active site of S-HPCDH the C2 methyl group clashes directly with a catalytic serine 
residue. The substrate binding pocket of R-HPCDH appears to have a more open 
conformation that can accommodate both substrate isomers with equal propensity. 
However, as mentioned by previous models [1], binding of the S-substrate in R-HPCDH 
likely leads to opposite orientation of substrate reactive groups at the catalytic site, and 
therefore effective catalysis does not occur for the S-substrate in R-HPCDH. These 
structural differences correlate nicely with kinetic data that indicated stereospecificity of 
S-HPCDH is provided by a large difference in the value of Km between different 
substrates isoforms, whereas stereospecificity of R-HPCDH is controlled by large 
differences in the value of kcat between different substrate isomers. To our knowledge, the 
analysis given in Chapter 4 represents the first side-by-side structural comparison of two 
SDR-enzymes that function together to act upon two alcohols in the same metabolic 
pathway. Furthermore, this information was essential to clarify the mechanisms of 
stereospecificity used by R-and S-HPCDH in the unique pathway of bacterial epoxide 







Summary: Air proteins and RNA regulation 
 
The conserved zinc knuckle proteins Air1 and Air2 (collectively referred to as Air 
proteins) are required for RNA processing and RNA surveillance in eukaryotes. Each Air 
protein functions as part of a trimeric protein complex called TRAMP (TRAMP4 and 
TRAMP5) [2-5], which serves to activate 3’-end degradation of targeted RNA substrates 
by the nuclear exosome. Previous studies have indicated that within TRAMP4 and 
TRAMP5 the Air proteins play a central role in both RNA binding and forming protein-
protein interactions [6-13] (Figure 6-1). However, the binding interactions between Air 
proteins and various binding partners (protein and RNA) have remained poorly 
characterized.  
The research presented in this dissertation has extended the knowledge of Air 
protein binding interactions, and provided a foundation for future research aimed at 
exploring Air protein function. The principal finding of this work regarding the Air 
proteins is the characterization of a previously unknown binding interface between Air2 
and another TRAMP component, the helicase Mtr4 (Chapter 5).  The binding region of 
the two proteins was narrowed down to the first 29 residues of Air2 and the RecA1 and 
RecA2 domains of Mtr4. Because the RecA domains of Mtr4 are used for binding and 
hydrolysis of ATP, binding of Air2 to this region could explain why both ATP binding 
affinity and helicase activity of Mtr4 are enhanced upon formation of the TRAMP 
complex [14, 15]. Notably, binding of accessory proteins has been shown to increase 
ATP affinity and helicase activity in many other helicases [16-20]. Molecular detail of 
the identified Air2-Mtr4 interaction and how such an interaction modulates Mtr4 activity 
remains to be determined through future biochemical and structural studies.   






Figure 6-1.  Characterized protein-protein and RNA binding interfaces of Air proteins. Air1 and Air2 sequences are aligned with 
conserved residues colored orange and semi-conserved residues colored light yellow. The indicated interactions are those 
characterized for Air2 binding to Mtr4 [6], tRNA [7], Trf4 [8], and Hmt1 (unpublished data). Colored triangles indicate specific 








In addition to binding Mtr4, the Air proteins also bind to different types of RNA 
and to other proteins such as the methyltransferase Hmt1 [13, 21] (Figure 6-1). These 
additional binding interactions of Air1 and Air2 are also not well characterized, and 
several outstanding questions remain about Air protein function in these 
processes.detailed description of future directions including existing preliminary data 
aimed at answering remaining questions regarding Air protein binding interactions is 
given below. 
 
Future directions: Air proteins and protein binding interactions 
 
 
Does Air2 modulate Mtr4 activity? 
  
 Fluorescence anisotropy studies have shown that Air2 residues 1-29 (Air21-29) can 
directly bind to the RecA domains of Mtr4 (Chapter 5), and it was postulated that binding 
of Air2 to this region may enhance ATP affinity and/or helicase activity. More 
compelling evidence is required to identify if binding of Air21-29 to Mtr4 results in 
modulation Mtr4 reaction parameters. This possibility can be easily tested in the Johnson 
lab using routine assays to analyze Mtr4 ATP binding [15], ATP hydrolysis [22], and 
helicase unwinding [22], all in the presence of unlabeled Air21-29 peptide. The Johnson 
lab currently has approximately 10 mg of unlabeled Air2 1-29 peptide (synthesized by 
Dr. Joshua Price at Brigham Young University) and other materials that are needed to 






How does the N-terminus of Air2 specifically interact with Mtr4 RecA domains? 
Characterization of the molecular interactions involved in forming the binding 
interface between Air21-29 and the Mtr4 RecA domains requires identifying the specific 
amino acids involved in binding. As mentioned in Chapter 5, Falk et al. recently reported 
a crystal structure and biochemical data that also identified that the N-terminus of Air2 
could associate with Mtr4 [6]. However, in that study none of the first 29 amino acids of 
Air2 were reported to bind to the RecA domains of Mtr4. Instead, the crystal structure 
showed that Air2 residues 7, 8, and 11 were directly bound to the Arch domain of a 
symmetry related Mtr4 molecule. Using fluorescence anisotropy, I was able to 
demonstrate that this interaction between Air2 and the Mtr4 Arch was likely not a 
genuine interaction but rather an artifact of crystallization (Chapter 5). The Falk et al. 
manuscript did however identify that residues 26 and 29 form hydrophobic interactions 
with Mtr4 Met1016 (domain4; ratchet domain). In vitro pull-down studies further 
confirmed this interaction, as substitution of Mtr4 Met1016 (M1016E) disrupted Mtr4 
interactions with GST-Air2.  Therefore, Air2 residues 26 and 29 likely form the binding 
interactions described by Falk et al, and do not bind the RecA domains. 
 Because TRAMP complexes are found throughout eukaryotes it’s likely that 
specific residues important for mediating important protein-protein interactions are also 
conserved. Therefore, primary sequence analysis of various Air2 homologues might serve 
as a useful tool to identify conserved residues that are important for binding to Mtr4. The 
sequence alignment of the N-termini of yeast Air homologues highlights that several 











In future research, these conserved sequences should be considered for site directed 
mutagenesis followed by additional binding studies with Mtr4 RecA domains to analyze 
their contributions to binding. In addition, if it is also confirmed that Air21-29 can 
modulate Mtr4 function, then these conserved residues are also great candidates for site 
directed mutagenesis to analyze their contribution to regulating Mtr4 activity.    
Obtaining a crystal structure of Air2 Air21-29 and Mtr4 would be an ideal way to 
identify specific binding residues and understand how binding interactions could impact 
Mtr4 function. Efforts to obtain crystals of Air21-29 and Mtr4 have been carried out with 
promising success. I have initiated sitting drop co-crystallization trials with a non-labeled 
Air21-29 peptide and both full length Mtr4 and an archless version of Mtr4. To date, 
several different crystal hits have been identified only in the trials containing archless 
Mtr4 (details can be found in Chapter 4). These crystals have not yet been analyzed for 
diffraction quality nor have they been confirmed to be protein. However, it’s likely that 
these crystals are indeed protein crystals, as none of the crystal hits contain crystals in the 
reservoir solution and most of the crystallization solutions do not contain compounds that 
typically form salt crystals. Furthermore, Regardless of diffraction quality, these initial 
crystallization hits provide a great foundation for future trials. 
 
 
Figure 6-2. N. terminus sequence alignment of Air protein homologues in yeast. 
Conserved sequences are highlighted orange. Semi-conserved sequences are 
highlighted light yellow. Residues are numbered according to Air2 sequence. 
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Do Air1 and Air2 exhibit a common binding mode for interaction with Mtr4? 
 In addition to fluorescence anisotropy studies which showed Air21-29 can bind full 
length and truncated forms of Mtr4 with similar affinity, I also demonstrated recombinant 
Air1 residues 1-41 (Air11-41)  can interact with full length Mtr4 in co-IP experiments 
(Chapter 5), suggesting that this region of Air1 binds to Mtr4 in a similar fashion as  
Air21-29. Notably, Air11-41 consists of sequences that are homologous to Air21-29. In order 
to more clearly verify that this region of Air1 and Air2 contains a common Mtr4 binding 
interface, additional binding studies are needed to determine if  Air11-41 also associates 
with Mtr4 RecA domains, and if the binding affinity (Kd) between Air11-41 and Mtr4 is 
comparable to that observed for Air21-29 and Mtr4. To this end, I have initiated 
preliminary studies using florescence anisotropy to analyze binding between an N-
terminal labelled Air11-41 peptide (synthesized by the Price lab at Brigham Young 
University) and recombinant full length Mtr4. All of the experimental parameters (i.e. 
instrumentation, buffer, temperature, protein concentrations, etc.) were analogous to 
previous anisotropy studies using Air21-29 (Chapters 4 and 5) However, unlike anisotropy 
studies with Air21-29, binding interactions between Air11-41 and Mtr4 was not detected. 
The reason for this observed difference between the Air11-41 and Air21-29 anisotropy 
results, and the discrepancy between Air11-41 anisotropy and Air11-41 co-IP results is not 
clear. One possibility could be that during anisotropy studies the Air1 peptide 
experiences non-specific binding interactions with itself that do not occur in the Air2 
peptide or during co-IP studies. This reasoning is based on the fact that Air11-41 contains 
12 additional residues (residues 4-11, 24-27) that are not observed in Air21-29 (Figure 6-2) 
It is possible that during anisotropy experiments, where the Air1 peptide has free-motion 
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in solution, the extra Air1 residues form non-specific binding interactions that prevent 
binding to Mtr4. In contrast, the co-IP experiments were conducted by first binding the 
FLAG-tagged N-terminus of Air11-41 to anti-FLAG resin prior to addition of Mtr4. This 
immobilization of the N-terminus of Air1 may have prohibited non-specific binding 
interactions, allowing Mtr4 to bind and co-immunoprecipitate with Air11-41. To 
circumvent such a problem, future researchers should consider using other methods for 
characterizing Air1-Mtr4 binding interactions in which the N-terminus of Air1 can be 
attached to a solid surface and remain stationary. One such method is SPR (Surface 
Plasmon Resonance), which is currently available at USU.  
 
Future directions: Air proteins and Hmt1 regulation 
 
In addition to their role in TRAMP mediated RNA degradation, Air1 and Air2 have 
also been reported to function as regulators of nuclear mRNA export. This regulation is 
attained by directly modulating the activity of the arginine methyltransferase protein Hmt1 
[21]. In budding yeast, methylation by Hmt1 is required to activate the nuclear mRNA 
transport protein Npl3. In its non-methylated state, Npl3 no longer effectively delivers 
mRNA to the cytoplasm. Air1 has been shown to directly inhibit Hmt1 methylation of Npl3 
in vitro and in vivo; suggesting that binding of Air1 to Hmt1 inhibits methylation, and thus 
inhibits mRNA export. Although it is clear that Air1 can function to inhibit Hmt1, details 
of how protein-protein interactions facilitate Hmt1 inhibition are unknown. In addition, 
Because Air2 can bind to Hmt1 in vitro, it has been assumed that Air2 also inhibits Hmt1 
activity. However, inhibition of Hmt1 by Air2 has never been reported. 
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Over the last two decades, the functional importance of protein arginine 
methylation has become more recognized. This post-translational modification has been 
shown to regulate many critical cellular processes including DNA repair, chromatin 
maintenance, gene expression, and translation [23]. Surprisingly, there are few examples 
of how methylation itself is regulated within the cell. Hmt1 is the primary arginine 
methyl transferase in S. cerevisiae, and Air1 is the only protein that has been shown to 
regulate its activity. Understanding the mechanistic details of how Air1 inhibits Hmt1 
activity would provide valuable insight to how arginine methylation is regulated in 
eukaryotes. As part of my dissertation work I have initiated research to address 
outstanding questions regarding Air protein mediated inhibition of Hmt1. In the text 
below, I describe preliminary data and future directions aimed at answering these 
questions.   
 
How do the Air proteins bind Hmt1? 
The first 54 amino acids of Hmt1 have been identified to be required for binding 
the Air proteins, but which regions of the Air proteins are involved in associating with 
Hmt1 have not been described. Therefore, to further identify the Air-Hmt1 binding 
interface my work has focused on identifying the protein regions of Air1 and Air2 
required for Hmt1 binding. As described in previous chapters, each Air protein contains 
five zinc knuckles that are flanked on each side by extended N- and C-terminal 
sequences. To identify which regions are important for binding Hmt1, I have designed 
several expression constructs of Air1 and Air2 truncation mutants (details in Chapter 4) 
which have been used to qualitatively assess Air-Hmt1 binding using in vitro pull-down 
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and gel filtration analysis. Preliminary data has indicated that the extended C-terminus of 
Air1 and Air2 is not required for Hmt1 binding. Pulldown experiments using FLAG-tag 
Air1 indicate that an Air1 protein containing the N-terminus through zinc knuckle 5 (Air1 
N-ZnK5) can bind Hmt1. Binding  is also observed with a more highly truncated Air1 
protein consisting of only zinc knuckles 4-5 (Air1 ZnK 4-5) (Figure 6-3A). Interestingly, 
Air1 ZnK4-5 appears to pulldown Hmt1 more effectively than the longer Air1 N-ZnK5 
protein. The reason for this increased binding by ZnKs 4-5 is currently not known. 
Although this data clearly indicates that ZnKs 4-5 of Air1 can effectively bind Hmt1, it 
does not exclude the possibility of additional binding by other regions of Air1. 
 
             










Figure 6-3. Protein binding analysis of Air proteins and Hmt1. (A) 
FLAG-tagged Air1 (N-ZnK5) and Air1 (ZnK4-5) pull down Hmt1 on 
anti-FLAG resin. Samples were run on SDS-PAGE and visualized by 
anti-His antibody. (B) Purified Hmt1 and Air2 (N-ZnK3) co-elute on 





Binding of Hmt1 by Air2 has been analyzed by gel filtration.  This analysis was 
conducted using individually purified Air2 (Air2 N-ZnK3) and Hmt1 proteins. Notably, 
due to protein availability, Air2 N-ZnK3 was the only isolated Air2 protein used in this 
experiment. Each protein was run separately and together over a gel filtration column 
(Superdex 200). Analysis of the chromatogram in Figure 6-3B shows that Air2 N-ZnK3 
and Hmt1 co-elute as a higher molecular weight peak compared to the individual 
proteins, indicating that Air2 N-ZnK3 and Hmt1 form a stable complex in vitro. It is still 
unknown whether Air2 ZnK4-5 can also bind to Hmt1. Future binding studies need to be 
conducted using additional truncation mutants of both Air1 and Air2 to assess (1) if they 
share common Hmt1 binding regions and (2) identify the smallest portion of each protein 
that binds Hmt1.  Once minimal binding regions have been identified, other binding 
analyses could be used (such as ITC, SPR, fluorescence anisotropy, or EMSAs) to 
quantify the various binding interactions and assess the binding contribution of particular 
regions (or residues) of the Air proteins. Such studies could additionally be used to 
identify tight-binding complexes that may hold promise for crystallization trials and x-ray 
diffraction.    
Obtaining high resolution crystal structures of Air1/2 and Hmt1 would be the 
most informative piece of data to characterize the Air-Hmt1 binding interface. I have 
initiated crystallization trials with Air2 truncation mutants and Hmt1 with success. These 
successful crystallization trials were performed using Air2 N-ZnK5 and an Hmt1 mutant 
which contained a point mutation at the thirteenth amino acid (K13S). As described in 
Chapter 4, both proteins were co-expressed using a pET-Duet1 plasmid and co-purified 
using affinity chromatography and gel filtration. Crystallization screening produced 
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crystals in many conditions. The most promising of these hits produced protein crystals 
that diffracted to 7 Å using a home-source x-ray generator at USU (Figure 6-4). An SDS-
PAGE gel confirmed that these crystals contain both Air2 and Hmt1. Furthermore, 
another crystal from that same condition was sent to the synchrotron source SSRL for 
diffraction analysis. Unfortunately that particular crystal had poor x-ray diffraction 
(~20Å). However, the diffraction pattern suggested that the crystal was indeed protein. 
Additionally, an x-ray excitation scan was conducted on that crystal at SSRL which 
detected the presence zinc ions, suggesting that the crystal contained zinc knuckles. 
Further optimization of this crystal condition may allow for x-ray diffraction of crystals 
to a resolution greater than 7Å. Future researchers are encouraged to chase this crystal hit 














Figure 6-4. Air2 (N-ZnK5)-Hmt1 crystals 




How do the air proteins regulate Hmt1 activity? 
 Although it has been established that Air1 inhibits Hmt1 mediated methylation of 
Npl3, the mechanism of inhibition is unclear. It has also remained unclear whether Air2 
also inhibits Hmt1 activity. A collaborative effort between our group (Johnson lab) and 
the Hevel lab group has begun preliminary studies to identify the mechanistic detail of 
Hmt1 inhibition by the Air proteins. These preliminary studies have involved using an in 
vitro methyltransferase assay (developed by the Hevel lab) to monitor Hmt1 methylation 
of Npl3. Using that assay it was shown that an Air1 protein consisting of N-ZnK5 can 
effectively inhibit methylation by Hmt1, but an Air1 protein consisting of N-ZnK3 could 
not. This observation indicates that ZnKs 4-5 of Air1 are required for inhibition of Hmt1. 
This result is consistent with the pull-down binding analysis (mentioned above) which 
indicated Air1 ZnK4-5 could bind to Hmt1. Interestingly, additional  methyltransferase 
assays showed no inhibition of Hmt1 when Air2 N-ZnK-5 was used in the reaction setup, 
indicating for the first time that Air2 does not inhibit Hmt1 methylation. This result 
highlights a critical flaw in the original Air-Hmt1 manuscript which concluded that Air1 
and Air2 are functionally redundant in their effect of Hmt1 activity. The molecular detail 
of the difference in Hmt1 inhibition by Air1 and Air2 is still unknown and is the subject 
of future work. 
It’s very intriguing that both Air1 and Air2 can bind Hmt1 but only Air1 inhibits 
methylation. A promising avenue for identifying the specific amino acids of Air1 
involved in Hmt1 inhibition is to identify sequence differences within ZnKs 4-5 of Air1 
and Air2. All current knowledge indicates that both Air1 and Air2 form a tight complex 
with Trf4 and Trf5 in vivo, and there is no evidence to suggest that either Air1 or Air2 
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exists independent of Trf4 or Trf5 in the cell. Therefore, Air1 sequences that should be 
considered as contributors to Hmt1 inhibition are those that differ from sequences in Air2 
and those that are not characterized as Trf4/Trf5 binding residues. Figure 6-5 highlights 
that the majority of such residues reside in the linker region (L4) between ZnK4 and 
ZnK5. In future studies those residues should be the target of site directed mutagenesis 
and construction of chimeric proteins. Those mutant constructs should then be tested in 













 The research presented in this dissertation has provided a promising foundation 
for future research efforts regarding Air proteins and their various binding interactions. 
Air-Mtr4 studies have identified an important binding interaction that can be explored 
using known techniques that are familiar to researchers in the Johnson lab. I have also 
narrowed down another binding interface between Air1 and Hmt1. My efforts in that 
project have provided a new and continuing avenue of research for both the Johnson and 
Hevel labs. In addition, I have developed purification protocols and initiated 
crystallization studies for both Air2-Mtr4 and Air2-Hmt1. Crystallization hits have been 
identified in each case, and future repetition and modification of those studies has great 
Figure 6-5. Sequence alignment of Air1 and Air2 zinc knuckles 4-5. Conserved residues 
are colored orange. Semi-conserved residues are colored light yellow. Blue triangles 
indicate residues that interact with Trf4 according to Air2-Trf4 structure (pdb 3NYB). 
Red arrows indicate Air1 residues that differ from Air2, and are potential targets for 
mutagenesis and functional studies. Residues are numbered according to Air2 sequence. 
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potential for leading to high resolution crystal structures. Future researchers are strongly 
encouraged to conduct follow-up crystallization studies. Furthermore, several crystals 
that were produced from Air2-Mtr4 and Air2-Hmt1 crystallization trials currently remain 
undisturbed in crystallization trays, and are awaiting x-ray diffraction analysis.  
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